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DEVELOPMENT OF NEUROTENSIN-BASED 
RADIOPHARMACEUTICALS FOR  
NEUROTENSIN-RECEPTOR-1-POSITIVE TUMORS TARGETING 
Yinnong Jia, Ph.D. 
University of Nebraska Medical Center, 2017 
Supervisor: Jered C. Garrison, Ph.D. 
The neurotensin receptor 1 (NTR1) is overexpressed in many cancers, due to 
its role as a growth pathway. These NTR1-positive cancers include pancreatic, colon, 
prostate and breast cancers. In the radiopharmaceutical field, the overexpression of 
NTR1 in cancer has prompted the development of NTR1-targeted diagnostics and 
therapeutics. The neurotensin (NT) peptide exhibits low nanomolar affinity for NTR1 
and has been the paradigm for NTR1-targeted agents. Since the 1980’s, radiolabeled 
NT analogs have been developed and evaluated for targeting NTR1-positive cancers. 
Since native NT is rapidly degraded in vivo by a variety of peptidases, a tremendous 
amount of effort has been put forth to design stabilized NT analogs with increased in 
vivo efficacy. To further enhance NTR1-targeted agents for diagnosis and therapy, our 
work has focused on strategies to increase the binding affinity, stability and optimize 
the pharmacokinetic profile of NTR1-targeted radiopharmaceuticals. In this 
dissertation, our work includes: 1) the investigation of the structure-activity 
relationship of the spacer groups in the NTR1-targeted agent design; 2) the evaluation 
of the effect charge distribution has on NTR1 binding and the biodistribution profile 




It is well known that 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA), and other radiometal chelators, can negatively impact the receptor binding 







]NT(6-13)), we evaluated a series 
of spacer groups to examine what steric impact, if any, DOTA had on NTR1-targeted 
peptides. We observed that the binding affinity was negatively affected by the direct 
conjugation (i.e., absence of spacer) with DOTA. However, the optimal binding 
activity can be restored with the inclusion of β-Ala or longer spacer groups. Our 
following studies investigated the impact the Lys
6
 charge had on NTR1 binding and 
the overall biodistribution profile. It was observed that translation of this amino acid 
further away from the peptide influenced the receptor binding, internalization and 
kidney retention profile of the NTR1-targeted peptide. Lastly, we examined if 
peptidase inhibitors, such as phosphoramidon (PA), would improve the targeting 
efficacy of NTR1-targeted agents. We observed that PA limited the degradation of the 
peptide and resulted in an increased NTR1-positive tumor uptake. Based on these 
findings, we increased our understanding of the structure-activity relationships and in 
vivo degradation of NTR1-targeted agents. Utilizing this knowledge, we plan on 
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1.1 Peptide-based radiopharmaceuticals 
Small molecules bearing radionuclides for targeting cancers have been of 
interest for diagnostic as well as therapeutic purposes [1–5]. One successful example of 




F-fluorodeoxyglucose), which exhibits 
high uptake in many cancers due to the reliance of cancers on glucose metabolism [6]. 
In order for a radiopharmaceutical to be considered successful, it must accumulate at a 
high level within the target tissues, as well as clear from the blood and other non-target 
organs in the time frame that is compatible with the half-life (t1/2) of the radionuclide 
[7–9]. One class of small molecules being actively investigated are regulatory peptides, 
such as the somatostatin, bombesin, cholecystokinin and neurotensin (NT), due to the 
favorable pharmacokinetic properties of these molecules [9–14]. Most 
receptor-targeted peptides that have been investigated for diagnosis and therapy are 
based on endogenous bioactive molecules [8,9,12,15–17]. Because of this and their 
relatively small size, receptor-targeted peptides are generally not antigenic [18]. 
Advantages of peptides over monoclonal antibodies, another class of molecules 
employed for tumor scintigraphy and treatment, include ease of synthesis and 
modification, ability to withstand harsher chemical conditions (i.e., acids and heat), and 
the significantly faster plasma clearance [19].  





]octreotide (Octreoscan™), a somatostatin peptide binding 
with high affinity to somatostatin receptors found at high densities in several 




]octreotide has been clinically 






Lu-labeled somatostatin analogues have been developed for 
peptide receptor radionuclide therapy (PPRT) to treat gastroenteropancreatic 
neuroendocrine tumors [7,10,21,22]. To improve the targeting capabilities of 
radiolabeled pharmacophores to somatostatin receptors, the field has evolved to the 
examination of radiolabeled somatostatin receptor antagonists that have shown 
superior pharmacokinetics in pilot studies [24,25]. The successes related to 
somatostatin receptor targeting has propelled the field forward into the development of 
other applicable regulatory peptide derivatives for tumor diagnosis and therapy 
[16,20,26–30]. Such peptides or peptide analogues investigated include, but are not 
limited to, bombesin [28], substance P [29], cholecystokinin [26,27] and neurotensin 
[31,32]. A representative list of receptor-targeted peptides under development is given 
in Table 1.1. 
In general, the components of receptor-targeted peptides include a peptide 
targeting vector, a chelator, a spacer group and a radiometal. The peptide targeting 
vector is responsible for obtaining target selectivity. The ideal peptide targeting vector 
is one with high in vivo affinity and stability to maximize target accumulation. 
Chelators, typically referred to as bifunctional chelating agents due to its metal binding 
and requisite conjugation chemistries, are utilized to stabilize radiometals and 
minimize the possibility of in vivo radiometal release [33–35]. For some 
receptor-targeted peptides, spacer groups are utilized to minimize steric inhibition of 
the pharmacophore by other structural components, such as the chelation system 
[36,37]. In addition, spacer groups can be a convenient handle to modify the 
hydrophilicity of the receptor-targeted agent without making structural changes to the 
targeting vector [36]. Lastly, the selection of the radiometal is based on the desired 




Table 1.1. Selected Peptides and Receptors in Tumors
a
 [19]. 
Peptide Receptor types Tumor expression 
Somatostatin  sst1, sst2, sst3, 
sst4, sst5 
Neuroendocrine tumors (gastroenteropancreatic 
tumors), lymphoma, paraganglioma, carcinoids, 
breast, brain, renal, small cell lung cancer, 
medullary thyroid cancer 
Bombesin/ 
GRP 
BB1, BB2, BB3, 
BB4 
Prostate, breast, pancreas, gastric, colorectal, 
small cell lung cancer 
VIP VPAC1, 
VPAC2 
Adenocarcinomas of breast, prostate, stomach 
and liver; neuroendocrine tumors 
α-MSH MC1-5R Melanomas 
CCK/gastrin CCK1, CCK2 Medullary thyroid cancer, small cell lung cancer, 
gastrointestinal stromal tumor, stromal ovarian 
cancer, astrocytomas 
Neurotensin  NTR1, NTR2, 
NTR3 
Small cell lung cancer, colon, exocrine ductal 
pancreatic cancer, Ewing sarcoma, meningioma, 
astrocytoma, breast, prostate cancer 
LHRH LHRH-R Prostate, breast cancer 
Substance P NK1, NK2, 
NK3 
Glial tumors (glioblastoma, medullary thyroid 
cancer), pancreas, breast, small cell lung cancer 
Exendin GLP-1 Insulinomas, gastrinomas, pheochromocytomas, 
paragangliomas and medullary thyroid 
carcinomas 
RGD  αvβ3-integrin Glioma, breast, prostate cancer 
a 
GRP, gastrin-releasing peptide; VIP, vasoactive intestinal peptide; α-MSH, 
α-melanocyte-stimulating hormone; CCK, cholecystokinin; LHRH, luteinizing 
hormone-releasing hormone; GLP, glucagon-like peptide; RGD, Arg-Gly-Asp 
5 




, α, and Auger emissions [7]. 
For diagnostic imaging, radiometals that emit γ photons and β
+
 particles are utilized for 
use with single photon emission computed tomography (SPECT) or positron emission 
tomography (PET), respectively. The commonly used radioisotopes and chelators of 













Lu have been investigated for SPECT imaging agent development 
[31,41–46]. In our studies, we utilized 
177
Lu (t1/2= 6.67 days) which is a theranostic 
radioisotope due to its dual γ photons and β
-
 emission profile [47,48]. 
177
Lu emits γ 
photons (113 and 210 keV) which have high enough energies to penetrate tissues and 







particles, a form of ionizing radiation that damages cellular DNA thereby killing 
affected cells [48]. To stably chelate 
177
Lu, we selected the 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, a common 
chelation system utilized in clinical medicine . DOTA has been shown to stably chelate 
177













Table 1.2. Characteristics of Radioisotopes and Chelators used for NT-based peptides. 










F) 1.8 h SFB Diagnosis (PET) 
Gallium-68 (
68
Ga) 1.1 h NOTA, DOTA Diagnosis (PET) 
Copper-64 (
64
Cu) 12.7 h DOTA Diagnosis (PET) 
Indium-111 (
111
In) 67.2 h DTPA, DOTA Diagnosis (γ imager) 
Lutetium-177 (
177
Lu) 160.8 h DOTA Diagnosis (SPECT) 
Rhenium-188 (
188
Re) 17.0 h (NαHis)Ac Therapy  
Thallium-201 (
201




1.2 Neurotensin receptors and cancers 
Neurotensin (NT) receptors have been found to be overexpressed as a growth 
pathway for the proliferation, survival, migration, invasion and neoangiogenesis of 
numerous cancers [49]. Reubi and coworkers [50] have observed overexpression of NT 
receptors in clinically relevant human tumors, such as Ewing’s sarcoma (65%), 
meningioma (52%), astrocytoma (43%), medulloblastoma (38%), medullary thyroid 
carcinoma (29%) and small cell lung cancer (25%). In addition to the above cancers, 
the occurrence of NT receptors has been reported in high abundance in ductal 
pancreatic adenocarcinoma (75%) [51,52], invasive ductal breast cancers (91%) [53,54] 
and malignant mesothelioma (90%) [55]. To date, the increased expression of NT 
receptors has been shown to contribute to the tumor progression in non-small cell lung 
cancer [56], colon adenocarcinoma [57], head and neck squamous cell carcinoma [58] 
and prostate cancer [59]. The high occurrence of NT receptors in such prevalent 
cancers has led to an increased interest in the development of imaging moieties for 
targeting NT receptors in the last three decades. Despite the ongoing research 
concerning radiopharmaceuticals for targeting NT receptors, to date only two clinical 
studies have been performed [41,60], both lacking the desired pharmacokinetic 
performances required for a successful radiopharmaceutical agent. 
Currently, there are four NT receptors that have been identified. Two of the 
identified receptors, NTR1 and NTR2, have been found in human and belong to the 
G-protein coupled receptor family, demarked by the seven putative transmembrane 
domains of this class [61,62]. NTR3, also found in human, belongs to sortilin family of 
proteins as an intracellular sorting protein and is composed of a single transmembrane 
8 
domain [62–65]. Recently, a fourth NT receptor (NTR4) belonging to the G-protein 
coupled receptor family was identified in bullfrogs [66]. 
Of most interest, with respect to cancer imaging and therapy, is the NTR1 
(424-amino-acid protein in rat and 418-amino-acid protein in human) which mediates 
most of the NT biological effects and is found overexpressed in various cancers 
[61,67,68]. The high expression of NTR1 in cancerous tissues is linked to signaling 
pathways in which NTR1 facilitates several transforming functions such as cell 
proliferation, migration, tumor angiogenesis, and metastasis [49,69,70]. The high 
NTR1 expression in numerous cancers, the minimal or lack of expression in normal 
surrounding tissues, and the fact that NT exhibits high affinity (Kd = 0.2 nM) for the 
NTR1 [71,72] has prompted the development NTR1-targeted radiopharmaceuticals 
[26,50–52,73,74]. 
1.3 NT and NTR1 
Initially isolated from the bovine hypothalamus [75] in 1973 and later obtained 
from the bovine intestines [76] in 1976 by Carraway and Leeman, NT is a 
13-amino-acid, linear peptide with the sequence of Glu-Leu-Tyr-Glu-Asn-Lys-Pro- 
Arg-Arg-Pro-Tyr-Ile-Leu. It has been shown to bind to NTR1 receptors with high 
nanomolar affinity. Functioning as both a neuromodulator and local hormone in 
mammals, NT is found in the central nervous system and peripheral tissues (mainly the 
gastrointestinal tract) [77–79]. Structural information concerning the molecular 
binding of the ligand NT to NTR1 has recently been published and has increased our 
understanding of the ligand-receptor interactions [62,72,80,81]. The binding 
interactions of NT to NTR1 were first investigated by Bernassau, Kitabgi, and 
Labbé-Jullié [72] utilizing alanine scanning and receptor mutagenesis methods, but 
9 
some details concerning the receptor/ligand interaction remained unclear. It was not 
until White and coworkers were able to obtain the crystal structure of NTR1, from 
Rattus norvegicus, binding to NT(8-13) that a detailed analysis of the ligand-receptor 
interactions was possible [62]. In this study, conformation thermostabilization of NTR1 
(NTR1-GW5-T4L) allowed the crystal structure of the active-like state to be obtained 
at 2.8 Å resolution (Figure 1.1). The structure of the NTR1 binding pocket was found to 
be composed of three extracellular loops (ECL1-ECL3) and six transmembrane helices 
(TM2-TM7). Of the findings, charge interactions were observed between the 
positive-charged arginine side chains of NT(8-13) and the electronegative rim of the 
binding site. The formation of a salt bridge between the C-terminus of NT(8-13) and 
R327 of the receptor is probable along with van der Waals interactions and three 
hydrogen bonds between the side chains of the central regions of NT(8-13) and the 
receptor [62]. As a consequence, these interactions result in directing the N-terminus 
end out of the binding pocket (Figure 1.2). These observations confirm previous studies 
that have shown that only the NT(8-13), C-terminus sequence (Arg-Arg-Pro-Tyr-Ile- 
Leu-OH) is needed for high binding affinity to the NTR1 [67]. Due to this, the majority 
of NTR1-targeted agents have utilized truncated NT sequence such as NT(8-13) and 










Figure 1.1. Overview of the NTR1 structure bound to the peptide agonist NT8–13.   
(a) side view (b) extracellular view and (c) intracellular view of the NTR1. 









Figure 1.2. The extracellular views of NTR1 binding pocket with NT(8–13). (a) the 
ligand-binding pocket (b) The interaction between NTR1 (green residues 
with grey labels) and NT(8-13) (grey residues with bold black labels). 
Dashed lines: hydrogen bonds and salt bridges. (c) The charge 
complementarity between NT(8-13) and its binding pocket (red, negative; 





1.4 The optimization of NT-based radiopharmaceuticals 
As with all targeted radiopharmaceuticals, the development of NT-based agents 
for cancer diagnosis and therapy has focused on increasing NTR1-positive tumor 
uptake, while minimizing non-target retention. In order to successfully translate the 
NT-based radiopharmaceuticals into the clinic, research have focused on increasing the 
stability and NTR1-affinity of agents under development. 
1.4.1 Degradation of NT 
The lack of plasma stability due to rapid degradation has been a major hurdle to 
overcome in the design of imaging and therapeutic agents based on NT. The rapid 
degradation of these peptides results in metabolites with no NTR1-affinity and, 
ultimately, leads to poor in vivo tumor uptake. For example, in a recent clinical study, 
the low tumor uptake of 
99m
Tc-Demotensin VI (N4-β-Ala-Arg-Dab-Pro-Tyr-Tle- 
Leu-OH), a NTR1-targeted agent, was attributed to the rapid degradation of this 
NT-based radiopeptide in vivo [41]. Findings such as this have given the impetus for the 
development of “stabilized” NT analogs with replacements using natural and unnatural 
amino acids. However, even with these replacements, we and others have observed that 
the in vivo degradation of “stabilized” NTR1-targeted agents, while inhibited, still 
occurs [85].  
To date, the major endogenous peptidases responsible for cleavages of NT have 
been revealed [86–88]. These four peptidases responsible for the NT degradation are 
zinc-dependent peptidase members of the metalloendopeptidase family [24,68,69]: (1) 
The neutral endopeptidase 24.11 (EC 3.4.24.11, neprilysin, NEP); (2) angiotensin- 
converting enzyme (EC 3.4.15.1， ACE); (3) metalloendopeptidase 24.15 (EC 
3.4.24.15, thimet oligopeptidase, TOP); and (4) metalloendopeptidase 24.16 (EC 
3.4.24.16, neurolysin). With respect to the NT(8-13) truncated sequence, TOP is 
13 






















 sites (Figure 1.3). To better understand the process and location of 
degradation, the distribution of these four peptidases have been reported [89]. NEP is a 
cell membrane-bound protein that is present on the vascular wall and is also distributed 
in tissues such as the kidney, intestine, lung and brain [89]. TOP is present in both 
soluble and membrane-bound forms that are widely distributed in tissues, such as the 
liver, brain, lung and kidneys [90,91]. Neurolysin and ACE are found in soluble forms 
located predominately in the cytoplasm of the cells. Neurolysin is distributed mostly in 
the kidney, brain and liver, while ACE is distributed in the lung, kidney, intestine and 
brain [89].  
1.4.2 Modification of NT-based radiopharmaceuticals to increase stability 
To radiolabel and stabilize NT from degradation, while retaining the high 
binding affinity of the targeting vector, many groups have focused on modifying the 
essential amino acid sequence of NT(8-13) [31,32,43,44,92]. The modifications that 
have been made to increase the metabolic stability of NT-based agents include 
introducing pseudopeptide bonds between amino acids, substituting selected amino 
acids with unnatural amino acids and/or N-methylation [31,32,43,44,92,93]. Below, we 
discussed how investigators have utilized these different modifications to stabilize the 
NT-based radiopharmaceuticals and the resulting biological effect caused by these 
















Figure 1.3. Peptide bond cleavage of NT. 
15 
 
1.4.2.1 Modifications at Arg8-Arg9 
The most common modifications to stabilize NTR1-targeted agents were made 




, due to the susceptibility of this peptide bond to 
proteolytic cleavage by TOP. Utilizing a DTPA-NT(8-13) analogue, Tourwé and 
coworkers modified the Arg
8
 by replacing it with a Lys. This modification was found to 
increase metabolically stability while still retaining high NTR1-affinity [94]. In 




 was replaced with a 
pseudopeptide isosteric bond Ψ(CH2-NH) to make it even more resistant to enzymatic 
cleavage. With these modification, the plasma stability increased from 10 min for 
111







demonstrating that these modifications substantially increased in vivo stability [94]. In 
regards to NTR1-binding affinity, these modifications were found to be well tolerated 
and still resulted in low nanomolar binding affinity. 





 could be made to stabilize the peptide without significantly 





 to evaluate the structure-activity relationship. The percentage of intact 
peptide increased from 0.9 ± 0.3 % after 4 h (t1/2= 39.4 min) to 6.5 ± 4.6% after 4 h  
(t1/2= 64.9 min) in blood serum [95]. 




 site has been to N-methylate the 
Arg
8
. Using DTPA-substituted NT analogues, Tourwé and coworkers found that 
N-methylation of the Arg
8
 did not influence the binding affinity significantly. The 
representative NT-based peptides, NT-20.1 (truncated structure), NT-20.2 (with one 
modification) and NT-20.3 (with two modifications) have been shown in Table 1.3. As 
16 
shown in the Table 1.4, the in vitro and in vivo stability has been improved more 
significantly in NT-20.3 with both N-methylation at Arg
8
 and the Tle
12
 modifications 
compared to NT-20.2 with only Tle
12
 modification [84]. The decreased binding affinity 
in NT-20.2 (41.2 ± 6.2 nM) has been restored with the dual-modifications in the 
NT-20.3 (15.9 ± 1.7 nM), as compared with the NT-20.1 (6.73 ± 0.31 nM). The 
internalization rate remained similar to an unmodified NT analog control, namely 
[Lys
6
(DTPA(In))]-N [84]. Most importantly, the DTPA-NT-20.3 exhibited the highest 
tumor uptake at 1 h (~3 fold higher than [Lys
6
(DTPA(In))]-NT, ~ 7 fold higher than 
DTPA-NT-20.1 and ~ 3.5 fold higher than DTPA-NT-20.2). Additionally, due to the 
higher tumor uptake, DTPA-NT-20.3 demonstrated the highest tumor to normal tissues 
ratios[84]. The improved stability and, as a consequence, the increased tumor uptake of 
DTPA-NT-20.3 demonstrates that this modification can substantially increase the 























DTPA-NT-20.1 Ac-Lys (DTPA)-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH 
DTPA-NT-20.2 Ac-Lys (DTPA)-Pro-Arg-Arg-Pro-Tyr-Tle-Leu-OH 
DTPA-NT-20.3 Ac-Lys (DTPA)-Pro-(NMe)Arg-Arg-Pro-Tyr-Tle-Leu-OH 
DOTA-NT-20.3 Ac-Lys (DOTA)-Pro-(NMe)Arg-Arg-Pro-Tyr-Tle-Leu-OH 













Table 1.4. The Binding Affinity, Stability and Tumor Uptake of the NT-Analogs with 
Modifications [44,84].  













at 1 h 
Tumor 
uptake 
at 3 h 
Lys
6
(DTPA)-NT 17.0 ± 4.0 25.0 ± 2.0 4.0 1.0 ± 0.3 0.7 ± 0.2 
DTPA-NT-20.1 6.7 ± 0.3 0.4 ± 0.02 0.8 0.5 ± 0.1 0.5 ± 0.1 
DTPA-NT-20.2 41.2 ± 6.2 4.4 ± 0.6 10.0 0.9 ± 0.3 0.5 ± 0.1 
DTPA-NT-20.3 15.9 ± 1.7 257.0 ± 71.0 26.5 3.3 ± 0.2 2.4 ± 0.2 
DOTA-NT-20.3 15.0 ± 1.0 ND 22.0 ± 1.0 4.7 ± 0.8 2.5 ± 0.2 
DOTA NT-20.4 190.0 ± 20.0 ND 16.0 ± 2.0 0.8 ± 0.1 0.5 ± 0.1 
a 
In vitro stability is expressed as the half-life in human serum at 37 °C 
b 
The percentage of intact peptide in plasma has been evaluated at 15 min after 
injection. 
c 
The tumor uptake was depicted as the %ID/g. 
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In contrast to modification at Arg
8
, the NT-20.4 utilizes the N-methylation of 
Arg
9
. This modification was found to dramatically decrease the binding affinity of the 
resulting analog. The IC50 value of In-DOTA-NT-20.4 increased dramatically to    
190 ± 20 nM from 15 ± 1 nM for In-DOTA-NT-20.3 [44]. With the decreased binding 
affinity, the NTR1-positive, tumor uptake of In-DOTA-NT-20.4 was only           
0.8 ± 0.1 % ID/g. In another study, the concurrent replacement of Arg
8
 by Gly(PipAm) 
and Arg
9
 by Gly(Pip) (as shown in Figure 1.4) resulted in a substantial loss of affinity 
relative to Arg
8
 modification alone [83]. Thus, during the pursuit of higher stability 
NTR1-targeted agents, the effect these modifications have on binding affinity should 
be carefully considered.  





 site were feasible and effective in increasing in vivo stability. These 
modifications led to approximately 10-20 fold increase in in vivo plasma stability 
relative to the native sequence. However, modifications to the Arg
8
 are generally 


















1.4.2.2 Modifications at Tyr11-Ile12 














 position are less tolerated and as a result the numbers of successful 





 have been listed in Figure 1.5. These modifications are believed to inhibit the 
degradation of the NT based peptide by ACE, NEP and neurolysin.  




 modifications, the structures of the 
NT-based examples are listed in Table 1.5. The replacement of Tyr
11
 by 
2,6-dimethyltyrosine (Dmt) is a common modifications. Many analogs has shown that 
this modification improves stability while preserving NTR1-binding affinity. For 
example, NT-XIX, which includes the Dmt
11
 modification, has similar binding affinity, 
but substantially increased stability relative to NT-XII, which lacks this modification 
[43,96]. However, other attempts at modifying or substituting Tyr
11
 have included the 
insertion of triazole rings or the replacement with mTyr [83]. These modifications have 
resulted in negligible improvement to the stability of the peptide and complete or partial 





 has been shown not to impact stability or NTR1-affinity [83]. This is somewhat 
unexpected since it has been shown that Tyr
11
 contributes (phenol group) to the binding 

































The position of Ile
12
 has been shown to be one of the most, if not the most, 
effective sites to increase the metabolic stability of NTR1-targeted agents [95]. For 
example, the replacement of Ile
12
 by Tle (tert-Leu) resulted in a stability increase from 
4.3% to 72% in human serum after 24 h incubation [83]. Although a significant 
reduction in the cell internalization rate and binding affinity was observed with this 
modification, the higher tumor uptake due to the increased stability made up for any 
loss in NTR1-affinity or internalization rate [95]. Interestingly, the insertion of a 
triazole at the position of Ile
12
, resulted in a more stable peptide, but a complete loss in 
binding affinity [95].  
1.4.2.3 Modifications at Leu13 
The modification at Leu
13
 is not commonly applied to increase the stability of 
NT-based radiopharmaceuticals considering that peptidase degradation at this site is 
limited and there is a risk of complete loss in NTR1 binding affinity. As mentioned 
previously, the crystal structure of NT(8−13) bound to NTR1 has demonstrated that the 
Leu
13
 participates in ionic and hydrogen bonding to the residues of the receptor [62]. To 
date, modifications of the Leu
13 
have not provide any substantial overall benefits in 
terms of metabolic stability and, in some cases, have adversely affected binding to the 
receptor. For example, Mindt’s group demonstrated that the insertion of triazole at the 
C-terminus resulted in a total loss of binding affinity [95]. In addition, the replacement 
of Leu
13
 by Cpa, Cha or tBuAla (Figure 1.6) decreased the binding affinity and did not 

















1.4.2.4 Enhancing stability using enzyme inhibitors 
Rather than modifying the structure of the NT based targeting vector, which can 
sometimes negatively impact affinity, the utilization of enzyme inhibitors to 
temporarily protect radiopeptides from in vivo peptidase degradation was first proposed 
by De Jong and colleagues [97]. Phosphoramindon (PA), the inhibitor of NEP has been 
shown to dramatically increase the in vivo targeting efficacy of receptor-targeted 
peptides, such as bombesin, gastrin/CCK and somatostatin analogs [97,98]. The 
increased in vivo targeting is associated with a decrease in NEP metabolism resulting in 
an increase in in vivo metabolic stability [97–100]. Two other NEP inhibitors, 
thiorphan and its prodrug racecadotril, have also been shown to increase the in vivo 
stability and tumor uptake of radiolabeled gastrin analogs (
111
In-DOTA-MG11); 
however, the effects of these analogs are not as potent as PA [101,102]. The 
co-injection of the ACE inhibitor, lisinopril showed no effect on increasing the tumor 
uptake of 
111
In-DOTA-MG11, which indicates that ACE is not significantly involved in 
the degradation of 
111
In-DOTA-MG11 [102].  
Because NEP and ACE are both responsible for the degradation of NT, we 
expect that co-formulating NEP and ACE inhibitors with NT-based peptides could be 
potentially beneficial. In our approach, we investigated PA (NEP inhibitor) and IPP 
(Ile-Pro-Pro, an ACE inhibitor) with NT analogs to evaluate the effect on the in vivo 
tumor uptake and stability. In addition, we investigated the effect of bradykinin (a 
competitive substrate for NEP, ACE and TOP) as well as a short peptide containing the 
most common metabolic sites of the NT(8-13) sequence (Pro-Arg-Arg-Pro-Tyr). These 
studies will be explored in Chapter 4. 
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1.4.3 The utilization of spacer groups to decrease steric inhibition and modify 
hydrophilic properties 
The insertion of spacer groups is considered an effective method to decrease the 
steric inhibition of receptor-targeted agents, thus restoring binding affinity. Common 






Ga. However, the introduction of DOTA too close to the NT pharmacophore 
can negatively impact binding affinity, particularly for those utilizing the smallest 
NT(8-13) fragment as a targeting vector. This loss of affinity is attributable to the steric 
bulk of the chelator. The introduction of various spacer groups in some NT analogs 
have been shown to restore optimal binding affinity by increasing the distance between 
the macrocyclic chelator and the targeting vector. For example, our studies have shown 
that the binding affinity of a NT(6-13) derivative was restored by the insertion of 
spacers groups, such as β-Ala, 5-Ava or 8-Aoc. This work will be further discussed in 
Chapter 2.  
In addition to reducing steric inhibition, spacer groups can also be utilized to 
easily adjust the hydrophilicity of receptor-targeted peptides. Hydrophilicity is an 
important factor to consider in order to achieve optimal target to non-target ratios. 
Analogs that are too hydrophilic may have reduced circulation times, while analogs that 
are too hydrophobic may have increased hepatobiliary clearance and poor tissue 
diffusion. To quantitate the hydrophilicity of a charged species in biological milieu, the 
distribution coefficient, LogD, is commonly used. The LogD values of various reported 
NTR1-targeted peptides are shown in Table 1.6. For example, DOTA-Ahx-NT(8-13) 
(
177
Lu(2)) has a LogD of -2.30, while DOTA-PEG4-NT(8-13) (
177
Lu-NT2) has a LogD 
of -2.40, suggesting that the PEG4 is able to increase the hydrophilicity of the analog 




Table 1.6. The Selected NT Analogs and LogD Values.  
Analogs Sequences LogD Ref 
177
Lu(2) DOTA-Ahx-NT(8-13) -2.30 [103] 
177
Lu-NT 1 DOTA-NT(8-13) -2.50 ± 0.30 [104] 
177
Lu-NT 2 DOTA-PEG4-Arg-Arg-Pro-Tyr-Ile-Leu -2.40 ± 0.20 [104] 
177
Lu-NT 3 DOTA-PEG4-Arg-Arg-Pro-Tyr-Tle-Leu -2.25 ± 0.03 [104] 
177
Lu-NT 4 DOTA-PEG4-Arg-Lys-Pro-Tyr-Ile-Leu -2.10 ± 0.10 [104] 
177
Lu-NT 5 DOTA-PEG4-Lys-Arg-Pro-Tyr-Ile-Leu -2.08 ± 0.01 [104] 
177
Lu-NT 6 DOTA-PEG4-Lys-Lys-Pro-Tyr-Ile-Leu -2.00 ± 0.10 [104] 
[
68
Ga]4 NODA-PEG6-Lys-Pro-Tyr-Tle-Leu -4.20 [105] 
[
68
Ga]6 DOTA-(ζ)Lys-Lys-Pro-Tyr-Tle-Leu -4.00 [105] 
[
68
































1.5 The optimization of NT-based radiopharmaceuticals to 
decrease renal uptake 
The high in vivo NTR1-targeting capabilities of NT-based 
radiopharmaceuticals has resulted in significant interest for the development of 
diagnostic and therapeutic agents based on this platform [44,45]. However, the high, 
non-specific kidney uptake, due to renal clearance, has been a concern with regard to 
the development of NTR1-targeted radiotherapeutic agents [44,45]. This situation is 
not new to the field of receptor-targeted peptide when considering that other peptides 
in clinical development, such as bombesin, somatosatin, minigastrin and CCK analogs, 
have been comprised by the high non-specific kidney uptake [106]. The significant 
amount of radioactivity remained in the kidney post-injection for peptide receptor 
radionuclide therapy (PPRT) could cause renal toxicity and possibly damage the 
kidneys after treatment [107].  
To further explain the reason of high kidney uptake in the next section, the 
general process of radiolabeled peptides after administration has been provided here 
[106,108]. After the injection and distribution, the majority of the radiolabeled peptides 
were excreted to the urine via kidney. The first step for kidney excretion is the 
glomerular filtration. The glomerulus is consisted of the loopy arteriole, where the ions, 
amino acids, glucose and water will be leaked under high pressure through the 
fenestrated endothelial cells on the vessel wall (with holes). During this process, the 
radiolabeled peptides are small enough to be efficiently filtered out from the blood in 
glomerulus to the Bowman’s Capsule and entered proximal tubule [106]. At the 
proximal tubule, majority of the filtered radiolabeled peptides will be reabsorbed back 
to blood, by multiple transport mechanisms (e.g., receptor-mediated endocytosis and 
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pinocytosis) [106,109]. The filtrate and water that are not reabsorbed at the proximal 
tubule will be excreted to the urine. 
1.5.1 Mechanisms of renal uptake 
The mechanism underlying the high kidney uptake of radiolabeled peptides has 
been of great interest in order to understand how to limit or decrease the kidney 
absorption of these agents. Based on our current understanding, two major uptake 
pathways have been identified: (1) receptor-mediated endocytosis by megalin and (2) 
fluid-phase endocytosis (pinocytosis) [106,107,109–111]. Other membrane 
transporters, such as organic anion and organic cation transporter, have been 
investigated, but none have yet to be found to be prominent players in the uptake of 
peptide-based radiopharmaceuticals [107]. Using [
111
In-DTPA]octreotide, a 
somatostatin analogue, de Jong and co-workers determine that the primary site of 
uptake in the kidney was the cortex [111]. Their subsequent work unambiguously 
demonstrated that megalin, a multiligand receptor found on many absorptive cell types, 
was a major contributor to radiolabeled somatostatin retention in the kidney [112]. 
Courtoy and Jamar’s group first identified the equal role of pinocytosis to the renal 
uptake of radiolabeled somatostatin analogues by using the proximal tubule-derived 
opossum kidney (OK) cell line [113]. Though the initial work identifying these uptake 
mechanism centered on somatostatin analogs, the same mechanisms of uptake have 
been shown to be relevant for all peptide-based radiopharmaceuticals 
[22,106,107,110,114]. A more detailed discussion concerning the megalin-mediated 
endocytosis and pinocytosis mechanisms are presented below. 
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1.5.1.1 Receptor-mediated endocytosis via megalin receptor 
The biodistribution of radiolabeled NT analogs in the kidneys has shown the 
same pattern of uptake as other radiopeptides (e.g., somatostatin, bombesin, 
neurotensin, minigastrin and CCK analogues), namely high retention in the cortex and 
low retention in the outer and inner medulla of the kidneys [22]. The high accumulation 
of radiopeptides in the cortex has supported the hypothesis that megalin, which is 
expressed predominately in the cortex, is one of the main uptake mechansims. Megalin 
is a large, membrane-associated receptor (600 kDa) that is mostly expressed in the 
proximal tubule and involved in the reabsorption of numerous endogenous substances 
[106,110]. Unfortunately, numerous studies have demonstrated that megalin also has 
high affinity for many peptide-based radiopharmaceuticals [109]. In one study, the 
renal uptake of radiolabeled peptides was significantly reduced after pre-incubation 
with known megalin ligands, such as albumin or receptor-associated protein (RAP) 
[107]. In addition, the role of megalin-mediated kidney uptake of radiolabeled peptides 
was further demonstrated with the significant decrease of uptake of 
[
111
In-DTPA]octreotide in a megalin-deficient mouse model compared to wild-type 
mice [112]. Similar findings were observed when evaluating the renal uptake of 
111
In-neurotensin, exendin and minigastrin in megalin-deficient mice compared to 
wild-type mice [106]. While our understanding of megalin ligand-selectivity is 
imperfect, studies to date have suggested that the positive charge state of most 
receptor-targeted peptide could be a major contributing factor in the uptake by the 
negatively charged megalin receptor [107].  
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1.5.1.2 Pinocytosis (fluid-phase endocytosis) 
Another transport mechanism that has been shown to contribute to the kidney 
uptake of radiolabeled peptides is fluid-phase endocytosis (pinocytosis) [107,113]. 
Using lucifer yellow, a pinocytosis marker, Courtoy and Jamar’s group demonstrated 
that a fluorescent somatostatin analog was taken up into proximal tubule endothelial 
cells by pinocytosis [113]. Following this study, Trejtnar and colleagues further proved 
the key role of pinocytosis in the renal uptake of several radiolabeled peptides by in 
vitro cellular studies [107]. They found that pre-incubation with an irreversible and 
selective pinocytosis inhibitor, rottlerin, significantly decreased pinocytotic uptake of 
several radiolabeled peptides, including 
177
Lu-labeled somatostatin, gastrin and 
bombesin analogs. Although the radiolabeled NT analogs were not tested in these 
studies, the generality of the uptake of numerous radiolabeled peptides supports the 
hypothesis that pinocytosis likely contributes to the accumulation of NT-based analogs 
in the renal proximal tubules [107].  
1.5.2 Impact of charge and charge distribution on NT uptake in the kidney 
To decrease the unfavorable kidney uptake of radiopeptides, the possible 
factors that influence the kidney uptake have been investigated. The impact of the 
charge state of radiopeptides on renal uptake has been reported by several different 
groups [17,22,27,107,115,116]. These studies revealed that the kidney uptake of these 
radiolabeled peptides were linearly increased with the number of charged amino acids 
[22,116]. For example, in one study which evaluates the addition of a negatively 
charged amino acid (i.e., Glu) to a radiolabeled bombesin construct, the decrease in net 
charge decreased the kidney uptake [117]. In contrast, increasing the positive charge of 
a somatostatin analog with the addition of basic amino acids increased the renal 
retention [106,115]. Considering the megalin discussion above, a large portion of the 
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renal uptake of radiolabeled peptides is carried out through a megalin-mediated process 
and this process is influenced by the charge of the peptide. Based on these and other 
studies, it seems highly likely that charge would be a factor in the uptake of 
NTR1-targeted agents. Recently, we have expanded on the investigation of the 
influence of charge by investigating how charge distribution in a radiolabeled NT 
analog could affect biological performance including its renal retention. Specifically, 
we designed NT analogs with the same overall charge state, but translated the charged 
amino acid (Lys) away from the targeting pharmacophore. A complete discussion of 
this study can be found in Chapter 3.  
1.5.3 Strategies for reducing kidney uptake  
Strategies to decrease the kidney uptake have been actively pursued. Some 
investigations have focused on modifying the peptide, particularly the charge state, to 
decrease renal retention. These modifications have general focused on substitution, 
addition or removal of charged amino acids [115,117]. However, these modifications 
can many times result in the loss of binding affinity and/or suboptimal biodistribution 
profiles. An alternative that has been actively explored is the utilization of blocking 
agents to reduce renal retention. Most of these agents are believed to reduce kidney 
uptake by blocking megalin-mediated uptake. Below are examples of the most 
commonly used approaches.  
1.5.3.1 Arg and Lys administration 
The administration of positively-charged amino acids, such as Arg, Lys, 
poly-L-lysine, D-Lys and their combination have been shown effective at decreasing 
the kidney uptake of some positively-charged radiopeptides [118–120]. The 
positively-charged Arg and Lys competitively bind to the megalin and saturate the 
receptor to decrease the non-specific binding of positively-charged radiopeptides (e.g., 
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NT-based peptides). For example, a clinical study using a targeted radiotherapeutic 
somatostatin analog demonstrated that the co-administration of Lys and Arg 
significantly decreased the renal uptake in patients [120]. Currently, co-infusion of 
basic charged amino acids (e.g., Arg and Lys) is the standard and common strategy to 
protect the kidney during PRRT [106]. 
1.5.3.2 Other strategies 
Besides the administration of Arg or Lys, pretreatment of albumin (a natural 
ligand for megalin) at low concentrations (0.5mg/ml) decreased kidney uptake for 






In-minigastrin) [114]. The inhibitory effect of the administration of albumin was 
proportionally related to the concentration that was employed. Other megalin blocking 
agents such as RAP [107] and fragments of albumin have also demonstrated the 
capability of decreasing the kidney uptake of radiopeptides [114]. Other strategies that 
have been investigated to reduce renal uptake and retention of the proximal tubule 
endothelial cells include: disruption of microtubule formation by colchicine or 
nocodazole [121,122], the administration of NH4Cl to neutralize the negatively charged 
binding site of megalin [123,124], and the inhibition of the citric acid cycle to disrupt 
the endocytic energy supply by maleate [123]. 
The studies on the mechanisms of renal uptake and the strategies that could 
efficiently decrease retention are still ongoing. More studies are needed to investigate if 
other transporters play a role in this endocytic process. Based on what is currently 
known of the proximal tubule cell absorption, there is no doubt that much work will be 
focused on the development of better methods and techniques for avoiding the retention 
of NTR1-targeted agents as well as other receptor-targeted peptides . 
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1.6 Current clinical studies 
Although NT-based radiopharmaceuticals has been under development for 
more than 30 years, only two clinical studies have been carried out [41,60]. In 2003, 
the first clinical study investigating an NTR1-targeted agent was reported. 
99m
Tc-NT-XI (see Table 1.5) was evaluated in four patients with pancreatic cancer. 
NTR1-mediated uptake was found to correspond to the NTR1-expression of the 
pancreatic tumors. Unfortunately, the overall pancreatic tumor uptake was relatively 
low compared to the non-target uptake in the intestine and kidneys, as well as to a 
lesser extent, in the liver, spleen and bone marrow. Eight years later, an additional 
clinical study was carried out using 
99m
Tc-Demotensin VI (N4-β-Ala-Arg-Dab-Pro- 
Tyr-Tle-Leu-OH) in patients with a variety of tumors types, including pancreatic 
adenocarcinoma (n =4), small cell lung cancer (SCLC) (n =4), non-small cell lung 
cancer (NSCLC) (n= 4), and colon carcinoma (n= 2). Tumor uptake was negligible 
for all patients. However, this was attributed to the rapid degradation of this analog in 
vivo and does not necessarily reflect on the potential of NTR1-targeted agents. These 
two clinical studies revealed that further development of NTR1-targeted agents is 
needed to reduce non-target retention, increase in vivo stability and determine the true 
potential of these agents for clinical translation.  
1.7 Summary and current proposal 
Due to its role as a growth pathway for cancer cell proliferation, invasion and 
migration, NTR1 has been shown to be overexpressed in many prominent cancers, 
including pancreatic, breast, and colon cancers. The high occurrence of NTR1 in these 
tumors provides a viable target for receptor-specific diagnosis and therapy. The 
NTR1-targeted ligands, typically based on the NT peptide, has been conjugated to 
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various radiometals and investigated for the diagnosis and therapy of NTR1-positive 
tumors. As discussed above, the development of NT-based radiopharmaceuticals has 
been comprised by the rapid degradation in vivo, reduced binding affinity due to the 
chelator (e.g., DOTA) and the high uptake in non-target tissues (e.g., kidney). To 
investigate solutions for these drawbacks and improve the biological performance of 
NT-based radiopharmaceuticals, we focused on approaches to better elucidate the 
structure-activity relationships and improve the potential of NTR1-targeted agents. 
In this dissertation, the work in the following chapters demonstrated the 
possible strategies that could be employed to increase the biological performance of 
NT-based radiopharmaceuticals. Specifically, we investigated: (1) the insertion of 
various spacers to optimize binding affinity, (2) the effect charge distribution of the 
NTR1-targeted agent had on pharmacokinetic performance and (3) the effect 
co-administration of enzyme inhibitors and competitive substrates had on the in vivo 
stability of an NTR1-targeted agent. Through the strategies and methods that we have 
investigated, we hope to move the field toward a better understanding of 




Chapter 2:  
Evaluation of DOTA-Chelated Neurotensin Analogs with 
Spacer-enhanced Biological Performance for 




Neurotensin receptor 1 (NTR1) is overexpressed in many cancers types. 
Neurotensin (NT), a 13 amino acid peptide, is the native ligand for NTR1 and exhibits 
high (nM) affinity to the receptor. Many laboratories have been investigating the 
development of diagnostic and therapeutic radiopharmaceuticals for NTR1-positive 
cancers based on the NT peptide. To improve the biological performance for targeting 
NTR1, we proposed NT analogs with DOTA chelation system and different lengths of 
spacers. 
We synthesized four NTR1-targeted conjugates with spacer lengths from 0 to 
9 atoms (null (N0), β-Ala-OH (N1), 5-Ava-OH (N2), and 8-Aoc-OH (N3)) between 
the DOTA and the pharmacophore. In vitro competitive binding, internalization and 
efflux studies were performed on all four NT analogs. Based on these findings, 
metabolism studies were carried out on our best performing conjugate, 
177
Lu-N1. 
Lastly, in vivo biodistribution and SPECT/CT imaging studies were performed using 
177
Lu-N1 in an HT-29 xenograft mouse model. 
As shown in competitive binding assay, the NT analogs with different spacers 
(N1, N2 and N3) exhibited lower IC50 values than the NT analog without a spacer 
(N0). Furthermore, N1 revealed higher retention in HT-29 cells with more rapid 
internalization and slower efflux than the other NT analogs. In vivo biodistribution 
and SPECT/CT imaging studies of 
177
Lu-N1 demonstrated excellent accumulation 
(3.1 ± 0.4 %ID/g) in the NTR1-positive tumors at 4 h post-administration.  
The DOTA chelation system demonstrated some modest steric inhibition of 
the pharmacophore. However, the insertion of a 4-atom hydrocarbon spacer group 
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restored optimal binding affinity of the analog. The in vivo assays indicated that 
177
Lu-N1 could be used for imaging and radiotherapy of NTR1-positive tumors. 
2.2 Introduction 
The neurotensin receptor 1 (NTR1) is a G protein-coupled receptor of the 
neurotensin receptor family, of which there are three known members [77]. NTR1 has 
been shown to be up-regulated in numerous cancer types, including colon [57], breast 
[53], and pancreatic cancer [52]. The overexpression of NTR1 has been attributed to 
cancer cells as a crucial growth signaling pathway [59,125]. Studies have shown a 
strong link between NTR1 expression and the progression of many cancer types 
[54,57,59].  
One area of NTR1 drug development being actively explored is 
NTR1-targeted diagnostic and therapeutic radiopharmaceuticals. The majority of 
these agents are based on neurotensin (NT), a 13-amino-acid peptide which exhibits 
nanomolar binding affinity to NTR1 [126]. The C-terminus of NT is responsible for 
binding to NTR1, thus research has focused largely on employing NT(8-13) and 
NT(6-13) fragments in drug development [68]. One major obstacle that has hampered 
the development of NTR1-targeted radiopharmaceuticals is the rapid proteolytic 













 bonds in the NT structure [127]. To enhance the potential 
of NTR1-targeted radiopharmaceuticals, Schubiger, Garcia-Garayoa and others have 
reported promising strategies to metabolically stabilize the NTR1-targeted agents 
[42–44]. These modifications consist of replacing selected amino acids at the 
degradation sites with non-natural counterparts to inhibit proteolytic cleavage. Among 
these stabilizing modifications, replacement of a secondary amide with a tertiary 
40 
amide (N-CH3) at the Arg
8 
position, replacement of Tyr
11 
with 2,6-dimethyl tyrosine 
(Dmt), and replacement of Ile
12
 with tert-leucine (Tle), have been shown to 
substantially inhibit degradation and improve in vivo stability [44,96].  
A principal chelator used in the design of radiometal-based theranostic agents 
is DOTA [44]. The primary reason for the extensive utilization of this macrocycle is 
its inherent in vivo stability with a variety of clinically relevant radiometals. The 
incorporation of DOTA on the N-terminus of the pharmacophore has been 
accomplished with diverse receptor-avid peptides [128]. However, for some peptides, 
placement of the DOTA chelation system too close to the pharmacophore can 
sterically interfere with the binding of the agent to the receptor of interest [129]. In 
this circumstance, inclusion of a linking group to increase the distance between DOTA 
and the pharmacophore can restore optimal binding [130,131].  
In this study, we investigated the extent to which distance between the DOTA 







]NT(6-13)) chosen for this study 
includes all three of the stabilizing modifications listed above. Hydrocarbon linking 
groups of various lengths (0 – 9 atoms) were incorporated between the DOTA 
chelation system and the N-terminus of the NT pharmacophore. Once in hand, the in 
vitro binding and cellular uptake properties of the NTR1-targeted conjugates were 
investigated in the NTR1-positive HT-29 human colon cancer cell line. Based on 
these results, we report the preliminary biodistribution and SPECT/CT studies of our 







Acetonitrile, formic acid, N,N-diisopropylethylamine (DIEA), 
N,N-dimethylformamide (DMF), dichloromethane (DCM), N,N'-dicyclohexyl- 
carbodiimide (DCC) , N-methylpyrrolidone (NMP), 4-(2-hydroxyethyl)-1- 
piperazineethane-sulfonic acid (HEPES), bovine serum albumin (BSA) and sodium 
dodecyl sulfate (SDS) were purchased from Fisher Scientific (Fair Lawn, 
NJ).  Fluorenylmethyloxycarbonnyl (Fmoc)-protected natural amino acids, 
Fmoc-β-Ala-OH, Fmoc-Leu-Wang resin (100-200 mesh), and (1-cyano-2-ethoxy- 
2-oxoethylidenaminooxy) dimethylamino-morpholino-carbenium hexafluoro- 
phosphate (COMU), were purchased from NovaBiochem (Hoherbrunn, Germany). 
Fmoc-N-Me-Arg(Pbf)-OH was produced by ChemPep, Inc. (Wellington, FL). 
Fmoc-2,6-dimethyl-L-tyrosine (Dmt) was from Ontario Chemicals, Inc (Guelph, ON, 
Canada). Fmoc-Tle-OH, Fmoc-8-Aoc-OH, and Fmoc-5-Ava-OH were purchased 
from CreoSalus (Louisville, KY). Lutetium-177 chloride (
177
LuCl3) was obtained 
from Perkin Elmer (Waltham, MA) with a specific activity of 32.3 Ci/mg. Naturally 
abundant lutetium chloride (
nat
LuCl3), triisopropylsilane and 
3,6-dioxa-1,8-octanedithiol were from Sigma-Aldrich (St Louis, MO). Neurotensin 
(NT) was purchased from American Peptide, Inc. (Sunnyvale, CA). McCoy’s 5A 
medium (1X; Iwakata & Grace Mod.) with L-glutamine was obtained from 
Mediatech, Inc. (Manassas, VA). TrypLE
TM
 Express was purchased from Invitrogen 
(Grand Island, NY).  
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2.3.2 Cell culture 
The human colon cancer cell line HT-29 was obtained from American Type 
Culture Collection (Manassas, VA) and cultured under vendor-recommended 
conditions. Cells were passaged twice weekly in McCoy’s 5A medium supplemented 
with 10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37 °C in a 
humidified incubator containing 5% CO2. 
2.3.3 Xenograft models 
All animal experiments were conducted in accordance with the Principles of 
Animal Care outlined by the National Institutes of Health and approved by the 
Institutional Animal Care and Use Committee of the University of Nebraska Medical 
Center. Eight-week-old Institute of Cancer Research severely combined 
immunodeficient (ICR SCID) mice were obtained from Charles River Laboratories 
(Wilmington, MA). Animals were housed five per cage in a light- and 
temperature-controlled environment. Food and water were given ad libitum. Bilateral 
HT-29 tumors were induced by subcutaneous injection of 4.0×10
6
 cells in Matrigel 
(BD Biosciences). The tumors were allowed to grow for 2-3 weeks reaching maximal 
1 cm in diameter before the mice were utilized in pharmacokinetic studies.  
2.3.4 Solid-phase peptide synthesis (SPPS) 
Peptides were synthesized on an automated solid-phase Liberty microwave 
peptide synthesizer from CEM (Matthews, NC), employing traditional Fmoc 
chemistry. Briefly, the Fmoc-Leu-Wang resin (100 µmol of the resin-substituted 
peptide anchors) was deprotected by piperidine, resulting in the formation of a 
primary amine from which the C-terminus of the growing peptide was anchored. 
Fmoc-protected amino acids (300 µmol) were activated with COMU and sequentially 
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conjugated to the resin. The resulting peptide was orthogonally deprotected and 
cleaved from the resin by shaking in a cocktail consisting of triisopropylsilane  
(0.125 ml), water (0.125 ml), 3,6-dioxa-1,8-octanedithiol (0.125 ml), and 
trifluoroacetic acid (4.625 ml) for 3 h. The cleaved peptide was subsequently 
precipitated and washed thrice using cold (0 °C) methyl-tert-butyl ether (40 ml×3). 
The crude conjugate was dried by a CentriVap concentrator and weighed. 
2.3.5 HPLC purification and analysis methodology 
HPLC/MS analyses were performed on a Waters (Milford, MA) e2695 system 
equipped with a Waters 2489 absorption detector and a Waters Q-Tof Micro 
electrospray ionization mass spectrometer. Sample purification for in vitro studies 
was performed on a Phenomenex (Torrance, CA) Jupiter 10 µm Proteo 250 × 4.6 mm 
C12 column with a flow rate of 1.5 mL/min. For bulk sample purification, a 
Phenomenex Jupiter 10 µm Proteo 250 × 10 mm C12 column was used with a flow 
rate of 5.0 mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid 
(solvent A) and acetonitrile containing 0.1% formic acid (solvent B). For unlabeled 
and 
177/nat
Lu-conjugates of N0 and N1, an initial gradient of 95% A: 5% B linearly 
decreased to 85% A: 15% B over a 15-minute time period. For unlabeled and 
177/nat
Lu-conjugates of N2, an initial gradient of 92% A: 8% B linearly decreased to 
87% A: 13% B over a 15-minute time period. For unlabeled and 
177/nat
Lu-conjugates 
of N3, an initial gradient of 90% A: 10% B linearly decreased to 85% A: 15% B over 
a 15-minute time period. At the end of the run time for all HPLC experiments, the 
column was flushed with the gradient 5% A: 95% B and re-equilibrated to the starting 
gradient. 
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2.3.6 Labeling with natLuCl3 
Naturally abundant 
nat
Lu was used to substitute for 
177
Lu in the ES-MS and in 
vitro binding studies. A sample of conjugates (0.10 mg, 0.06 μmol ) was dissolved in 
ammonium acetate buffer (0.5 M, 200 μL, pH 5.5) and mixed with a solution of 
nat
LuCl3 (1.7mg, 6 μmol). The solution was heated for 60 min at 90 °C. After cooling 
to room temperature, 
nat
Lu-conjugates were then peak purified by RP-HPLC in the 
same conditions above. All 
nat
Lu-conjugates were ≥ 95% pure before mass 
spectrometric characterization and in vitro binding studies were performed. 
2.3.7 Radiolabeling with 177LuCl3 
A sample of the conjugates (50 µg, 30 nmol)) was dissolved in ammonium 
acetate buffer (0.5 M, 100 μL, pH 5.5). 
177
LuCl3 (37 MBq, 1 mCi, 0.18 nmol) was 
added to the vial containing the conjugate, and the solution was heated for 60 min at 
90 °C. To separate radiolabeled peptides from unlabeled peptides on HPLC, 4-5 mg 
CoCl2 were then added and incubated for 5 min at 90 °C to increase the 
hydrophobicity of unlabeled conjugates[132]. After cooling to room temperature, 
evaluation and purification of radiolabeled conjugate were performed on a Waters 
1525 binary pump equipped with a Waters 2489 absorption detector and a Bioscan 
(Poway, CA) Flow Count radiometric detector system. The collected radioconjugate 
was concentrated with an Empore (Eagan, MN) C18 high performance extraction disk 
followed by elution with ethanol/sterile saline solution (6:4, 400 μL) to provide the 
radiolabeled conjugates in high purity.   
2.3.8 Distribution coefficient 
The distribution coefficient was determined (n = 6, 2 technical (tech) and    
3 biological (bio) repeats) for each 
177
Lu-labeled conjugate. In a 1.5 ml centrifuge 
tube, 0.5 mL of 1-octanol was added to 0.5 mL phosphate-buffered saline (pH 7.4) 
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containing the radiolabeled peptide (500,000 cpm). The solution was vigorously 
stirred for 2 min at room temperature and subsequently centrifuged (8000 x g, 5 min) 
to yield two immiscible layers. Aliquots of 100 µL were taken from each layer and 
the radioactivity of each was quantified by an LTI (Elburn, IL) Multi-Wiper nuclear 
medicine gamma counter.  
2.3.9 Receptor saturation 
Receptor saturation studies were performed (n = 6, 2 tech and 3 bio repeats) 
using 
177
Lu-N1 on the human colon cell line HT-29. HT-29 cells (1×10
6
) were 
suspended in 1.5 ml low retention centrifuge tubes with 100 µl McCoy’s medium  
(pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA). 
177
Lu-N1 (200,000 cpm, 100 µl) 
and a series of 100 µl N1 concentrations ranging from 0.469 nM to 120 nM were 
added for 45 min at 4 °C. Non-specific binding was determined using 3 µM N1 in the 
presence of the radioligand. The specific activity was determined as total binding 
activity minus non-specific binding. At the end of the incubation time, cells were 
aspirated and washed five times with cold medium and the remaining radioactivity 
was measured by gamma counter. Non-linear regression analysis was then performed 
using GraphPad Prism 5 (La Jolla, CA) to determine the Bmax and Kd values for each 
experiment. 
2.3.10 In vitro competitive binding studies 
For in vitro binding studies, the half maximal inhibitory concentration (IC50) 
for each conjugate was determined (n = 6, 2 tech and 3 bio repeats) for each 
177
Lu-labeled conjugate using the human colon cancer cell line, HT-29. In these 
studies, 
177
Lu-N1 served as the control and as the radioligand for comparing the 
relative effectiveness of the conjugates (N0-3 and NT). Briefly, HT-29 cells (~1×10
6
) 
were suspended in 100 µl McCoy’s medium (pH 7.4, 4.8 mg/mL HEPES, and      
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2 mg/mL BSA) and incubated at 37 °C for 45 min in the presence of radiolabeled 
177
Lu-N1 (100,000 cpm, 100 µl) and various concentrations of the unlabeled 
conjugates and 
nat
Lu-conjugates (100 µl). At the end of the incubation, the cells were 
centrifuged, aspirated and washed with media five times. The cell-associated 
radioactivity was measured using a gamma counter and the IC50 values determined by 
nonlinear regression using the one-binding site model of GraphPad Prism 5 (La Jolla, 
CA). 
2.3.11 In vitro internalization and efflux studies 
Internalization studies were performed (n = 6, 2 tech and 3 bio repeats) for 
each 
177
Lu-labeled conjugate using HT-29 cells in 1.5-ml centrifuge tubes. HT-29 
cells (~1×10
6
) were suspended in 100 µl McCoy’s media (pH 7.4, 4.8 mg/mL HEPES, 
and 2 mg/mL BSA). Cells were incubated for various times up to 2 h at 37°C in the 
presence of 100,000 cpm of each 
177
Lu-radioconjugates. During the incubation, at 
time points 15, 30, 60 and 120 min, cells were washed five times with media to 
remove the unbound peptide. Surface-bound radioactivity was removed by washing 
the cells twice with an acidic buffer (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8).  
The amount of radioactivity in each cellular pellet was measured as the internalized 
fraction by gamma counter.   
For efflux studies, HT-29 cells (~1×10
6
) were incubated in six-well plates 
overnight. On the day of the experiment, HT-29 cells were first incubated for 2 h at 
37°C in the presence of 100,000 cpm of each of the 
177
Lu-radioconjugates to reach the 
plateau of internalized radioactivity. Upon completion of the incubation, cells were 
washed five times with medium to remove the unbound peptide. Then, fresh medium 
was put in each well as the reservoir for efflux. At 0, 1, 2, 4 and 24 h, the medium for 
each time point was harvested for quantitative analysis of ligand efflux. 
47 
Surface-bound radioactivity was removed by washing the cells twice with an acidic 
buffer (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8). The cells were then lysed at 
37°C using a 10 % aqueous SDS solution to quantify the remaining internalized 
fractions. The radioactivity in the effluxed, surface-bound and internalized fractions 
for each radioconjugate was determined using a gamma counter. The effluxed fraction 
is expressed as a percentage of the total amount, which is the sum of the effluxed, 
surface-bound and fraction remaining in the cell. 
2.3.12 Metabolic stability  
The stability of 
177
Lu-N1 in human serum and cell medium was determined. 
Conditioned medium refers to medium in which cells were cultured at least for one 
day, as medium obtained under these conditions is believed to contain proteases 
excreted from HT-29 cells. The conditioned medium was prepared by centrifuging at 
4000 x g for 2 min to remove cells or cell debris. Briefly, 50 µL of HPLC-purified 
peptide in PBS (1.85 MBq, 50 µCi, 15 ng) was added to 50 µL human serum (MP 
Biomedicals, LLC (Solon, OH)) or conditioned medium and incubated at 37 °C for up 
to 24 h. After the incubation, 100 µL of a mixture of ethanol and acetonitrile     
(v/v = 1:1) was added to precipitate the serum proteins. The resulting mixture was 
centrifuged at 12000 x g for 10 min. The supernatant was collected and purged with 
N2 gas for 20 min to remove the ethanol and acetonitrile. The resulting sample was 
dissolved in 100 µL water and injected into RP-HPLC for analysis using the gradient 
described above. 
2.3.13 In vivo biodistribution studies 
Biodistribution studies were carried out using HT-29 tumor bearing SCID 
mice. Each mouse (average weight, 20 g) received an intravenous bolus, via the tail 
vein, of the radio-RP-HPLC purified 
177
Lu-N1 (280 kBq, 7.5 µCi, 2.25 ng) in 100 μL 
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of saline. Four-hour post injection, the mice were sacrificed and the amount of 
radioactivity in the tumors and other tissues (blood, heart, lung, stomach, pancreas, 
spleen, liver, kidneys, small intestine and colon) were counted by gamma counter. 
The excised tissues were weighed and results were expressed as percentage of 
injected dose per gram of tissue (%ID/g). Biodistribution radiation was measured with 
a NaI (Tl) well detector from AlphaSpectra, Inc. (Grand Junction, CO). Blocking 
studies were carried out by co-injection with excess unlabeled N1 (250 μg). 
2.3.14 SPECT/CT imaging with 177Lu-N1 
For SPECT/CT imaging studies, HT-29 tumor xenograft mice were injected 
i.v. with 
177
Lu-N1 (37 MBq, 1 mci, 300 ng) in 100 μL of saline and sacrificed for 
scanning 2 h post-injection. Images were acquired for 1 h using a FLEX Triumph 
single photon emission computed tomography system/X-ray computed tomography 
(SPECT/CT) and software (Gamma Medica, Inc., Northridge, CA). 
2.3.15 Statistical analysis 
Comparisons of each two groups for IC50, internalization and efflux studies, 
were analyzed by the unpaired two-tailed Student’s t test, and P values of less than 0.05 
were considered statistically significant.  
2.4 Results 
2.4.1 Synthesis and radiolabeling 







]NT(6-13) paradigm depicted in Figure 2.1, 
where X represents a series of hydrocarbon linkers of increasing length. Initial 
attempts at the synthesis of the peptides by SPPS gave unacceptably poor yields. 
Evaluation of the crude material by LC-MS revealed that a significant portion was 
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composed of terminated peptide chains and deletion peptides that originated at or after, 
respectfully, the N-methyl arginine. With the premise that the steric of the secondary 
amine were negatively affecting coupling yields, we made the following 
modifications to our SPPS protocol: 1) for all coupling reaction, the concentration of 
the coupling agent, COMU, was increased 4-fold, from 0.125 M to 0.5 M; 2) the time 
allowed for Fmoc-deprotection of all amino acids was increased 2-fold, from 3 min to 
6 min; and 3) for the two amino acids directly following the N-methyl arginine, the 
coupling time was increased from 5 min to 10 min and the reaction temperature was 
increased from 75 °C to 95 °C. With these modifications, the isolated yields of 
conjugates N0-3, after RP-HPLC purification, were substantially improved from less 
than 1% to greater than 10%. The purified conjugates were subsequently labeled with 
177/nat
LuCl3 (t½ = 6.75 days for 
177
LuCl3) by co-incubation in an ammonium acetate 








Lu-N3 were 91%, 94 %, 98% and 95%, respectively. 
RP-HPLC retention time, mass spectrometric identification and yields of the 
unlabeled conjugates and 
nat




























Table 2.1. Characterization, Yields, and IC50 values of NT analogs. 






Yields IC50 ± SD (nM) 
N0  1469.9 1470.9 13.1 10.6%  52.3 ± 1.5 
N1 1540.9 1541.9 13.9 11.1%  27.6 ± 1.3 
N2 1568.9 1569.9 10.8 10.0%  20.8 ± 1.4 
N3 1611.0 1611.9 11.3 10.2% 21.1 ± 1.7 
nat
Lu-N0 1641.9 1642.8 10.6 78.1%  47.2 ± 1.2 
nat
Lu-N1 1712.9 1713.8 11.7 71.2%  27.2 ± 1.1 
nat
Lu-N2 1740.9 1741.8 10.4 72.2%  24.3 ± 1.1 
nat
Lu-N3 1783.0 1783.8 9.6 86.7% 20.3 ± 1.2 




2.4.2 Distribution coefficient 
To evaluate the impact of the hydrocarbon linkers on water solubility of the 
radioconjugates, the octanol-PBS distribution coefficients at pH 7.4 were measured. 








Lu-N3 were       
-3.45 ± 0.05, -3.15 ± 0.05, -3.11 ± 0.05 and -2.99 ± 0.03, respectively.  
2.4.3 Receptor saturation 
To establish the surface expression of the NTR1 on the HT-29 cell line, receptor 




Lu-N1 bound well to the 
surface of HT-29 cells, and this binding could be blocked with the addition of unlabeled 
NT, thus implying the specific blockage of NTR1. From these studies, carried out at     
4 °C to prevent receptor-mediated endocytosis, the NTR1 expression was found to be 
85000 ± 1000 binding sites per HT-29 cell with a dissociation constant (Kd) of        









Figure 2.2. Receptor saturation study for N1. 
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2.4.4 In vitro competitive binding studies 
The NTR1 binding affinity of the unlabeled conjugates and 
nat
Lu-conjugates 
was investigated by competitive binding studies using HT-29 cells. Both unlabeled 
conjugates and 
nat
Lu-conjugates demonstrated nanomolar binding affinities. The IC50 
values for unlabeled N1, N2 and N3 were in the same range as full NT peptide. In 
contrast, the IC50 value for unlabeled N0 was higher than that of NT (P < 0.01), 










Lu-N3 (P < 0.01) (Table 2.1). 
2.4.5 In vitro internalization and efflux studies 
The effect of the linker modifications on the rates of internalization (Figure 2.3) 
and efflux (Figure 2.4) of the radioconjugates was investigated in HT-29 cells. The 
cellular uptake of the radioconjugates, represented as a percentage of total activity 
added, was evaluated at 15, 30, 60, and 120 min time points. The cellular uptake 






Lu-N3, the internalization of these radioconjugates was essentially identical over the 
initial 60 min time period. However, by 120 min post-incubation, a statistically 






Lu-N3 (3.69% ± 0.17%, 3.14% ± 0.10%, 2.74% ± 0.02%, respectively,             
P < 0.0001 ). After the 15 min time point, 
177
Lu-N1 demonstrated substantially higher 
levels of uptake (2.66% ± 0.02%) relative to the other radioconjugates. By the 120 min 
time point, 
177
Lu-N1 had the highest level of overall uptake with 4.38% ± 0.10% of 
total activity added. 
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Efflux studies were conducted to determine if a structure-activity relationship 
exists with regard to the externalization of the internalized radioconjugates. The efflux 
of these radioconjugates was investigated at the 1, 2, 4 and 24 h time points. At 1 h 
post-incubation,
 177
Lu-N2 demonstrated higher levels of effluxed radioactivity     
(26% ± 0.8%) relative to the other radioconjugates (18-21%). However, the percentage 
of externalized radioactivity was largely indistinguishable for all of the radioconjugates 
investigated by 2 h. At the 4 h time point, the effluxed fraction for 
177
Lu-N1       






Lu-N3 (33% ± 2.5%,   
34% ± 0.9% and 36% ± 3.6%, respectively, P < 0.01). Overall, the percent of initial 
internalized radioactivity effluxed from the cells ranged from 25-32 % by the 24 h time 
point. 
2.4.6 Metabolic stability 
NT is known to be susceptible to serum proteases [127]. The targeting vector 
used in our radioconjugates contains modifications to inhibit metabolic cleavage [44]. 
To establish if the structural modifications, the DOTA, or the N-terminal linker 
altered metabolic stability, the stability of 
177
Lu-N1 was investigated over a 24 h 
period in PBS (not shown), the conditioned (used) medium, and human serum. Under 
the conditions of the study, > 95% of the radioactivity was recovered for analysis 
from each sample. Evaluation of these samples by radio-RP-HPLC revealed no 









Figure 2.3. Time course following the uptake of 
177
Lu-radioconjugates, both 
internalization and surface bound, by HT-29 cells. Values are      













Figure 2.4. Time course following the percent efflux of the internalized 
177










Figure 2.5. Stability of 
177
Lu-N1 in conditioned medium and human serum. Panel A: 
chromatograph of 
177
Lu-N1 at start of the study, Panel B: chromatograph 
of 
177
Lu-N1 after 24 h in conditioned medium, and Panel C: 
chromatograph of 
177
Lu-N1 after 24 h in human serum. (x-axis: running 




2.4.7 In vivo biodistribution and imaging studies  
Based on the in vitro studies, 
177
Lu-N1 was deemed our best overall candidate 
as a balance of the affinity, internalization and efflux. Therefore, 
177
Lu-N1 was chosen 
for our preliminary in vivo investigation. Using the HT-29 xenograft mouse model, we 
evaluated the in vivo biodistribution of 
177
Lu-N1 at the 4 h time point, data given in 
Figure 2.6. The i.v. administered 
177
Lu-N1 effectively cleared from the blood      
(0.02 ± 0.01 % ID/g) by 4 h. As expected given the hydrophilic nature of 
177
Lu-N1, the 
clearance of radioactivity preceded largely through the renal system with            
86.3 ± 6.0 %ID being excreted in the urine. As a result of the high renal clearance, the 
kidneys exhibited significant retention (17.0 ± 2.2 %ID/g) at the 4 h time point. In 
addition, both the small and large intestines, known to be NTR1-positive tissues, 
exhibited retention of 1.4 ± 0.3 and 0.6 ± 0.1 %ID/g. This retention was largely found to 
be NTR1-receptor mediated as it could be effectively blocked by co-injection of 250 µg 
of unlabeled N1. For all other non-target tissues, 
177
Lu-N1 demonstrated good overall 
clearance. At the 4 h time point, 
177
Lu-N1 displayed good in vivo tumor targeting and 
retention, with a total accumulation of 3.1 ± 0.4 %ID/g. Accumulation in the tumor was 
shown to be NTR1-receptor specific with 86.6 ± 4.5 % reduction in uptake upon 
blocking. The ratio of tumor to blood was 123 ± 10, tumor to kidney was 0.2 ± 0.02, 






Figure 2.6. Graph of the biodistribution data at 4 h p.i. for 
177
Lu-N1 in SCID mice 
with HT-29 xenografts. The radioactivity accumulation is expressed as a 
percentage of injected dose per gram (%ID/g). Values are means ± SD    
















Tumor/blood 123.07 ± 9.81 3.91 ± 1.14 
Tumor/kidney 0.17 ± 0.02 0.02 ± 0.00 
Tumor/liver 9.33 ± 1.57 0.82 ± 0.16 
Tumor/muscle 110.97 ± 10.34 2.03 ± 0.70 
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Using microSPECT/CT, we evaluated the imaging potential of 
177
Lu-N1 at 2 h 
post-administration (Figure 2.7). Overall, the images correlated well with the 
biodistribution studies carried out at the 4 h time point. With the exception of the 
kidneys, little signal was observed in non-target tissues. The uptake of 
177
Lu-N1 in the 
HT-29 tumors was clearly visible in the flanks of the mice. As expected, the kidneys, 
the major pathway for biological clearance, were also readily observed.  
2.5 Discussion 
To date, NTR1-targeted peptides have been labeled with a number of clinically 






Ga [44,96,103,133,134]. In recent years, 
177
Lu, a theranostic radioisotope, has received increasing attention for potential clinical 
applications due to its dual emission characteristics [48,135–137]. Upon decay, 
177
Lu 
emits therapeutic beta particles (Eavg = 133 keV) and gamma rays (113 and 210 keV, 
6% and 10%) that are suitable for SPECT diagnostic imaging. Using 
177
Lu allows the 
potential for one radiopharmaceutical to be used as both a diagnostic and 





for imaging and therapy. In general, the goal of any chelation system in a 
radiopharmaceutical design is to retain the radionuclide during its in vivo lifetime. The 
most common polyaminocaboxylate chelator utilized in NTR1-targeted agent design is 
diethylenetriamine pentaacetic acid (DTPA) [31,44,84,138]. Unfortunately, DTPA 
forms a complex with 
177
Lu that in known to be unstable in vivo [139]. Conversely, 
DOTA, due to its cyclic nature and steric inhibition, is known to form in vivo stable 
177
Lu complexes, as demonstrated by numerous preclinical and clinical studies 
[135,137,139]. At the same time, DOTA, when placed too closely to the 
pharmacophore, has been shown to sterically inhibit the efficacy of receptor-targeted 









Figure 2.7. SPECT/CT image of 
177
Lu-N1 in a HT-29 xenograft mouse model at 2 h 











]NT(6-13)). To that end, we 
synthesized and evaluated a series of these NTR1-targeted conjugates, structurally 
depicted in Figure 2.1, with hydrocarbon linkers of 0, 4 (β-Ala), 6 (5-Ava) and 9 (8-Aoc) 
atoms in length. 
Under our standard SPPS conditions, initial attempts to synthesize the 
conjugates, N0-3, in good yield was unsuccessful. Analysis of the crude material 
revealed that the majority of the peptides formed were termination or deletion products 
that stem from the incorporation of the N-methyl arginine at position 8. This is not too 
surprising given that it is recognized that the formation of N-methylated amides can be 
more difficult due to increased steric interference [140]. Adjustments to more vigorous 
conditions (i.e., increased temperatures and longer reaction times) gave substantially 
better yields of the desired peptides.  
Receptor saturation studies of NTR1-positive HT-29 human colon cancer cells 
revealed a receptor density of approximately 85,000 ± 1000 per cell and a Kd value of 
42 ± 8 nM. Relative to literature, our determined Kd is higher than values reported from 
other groups (1.5- 15 nM), but this moderate difference in values is likely attributable to 
different experimental conditions (e.g., different ligands and temperature) [43,141,142]. 
Of particular note, our studies were performed at 4 °C to inhibit internalization; while, 
literature reports were carried out at 24 or 37 °C. At these elevated temperatures, the 
internalized activity would likely lead to an overestimate (lower value) in the 
disassociation constant.  
Based on the competitive binding assays, 
177
Lu-N0, as well as the unmetallated 
peptide (N0), exhibited binding affinities that were roughly two fold lower than the 
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corresponding analogs with hydrocarbon linkers. While this decrease in binding 
affinity is relatively modest, it does show that the steric bulk of the DOTA affects the 







Inclusion of a 4 atom hydrocarbon linker (i.e., β-Ala) appears to alleviate the steric 
inhibition of the chelator. Extension of the hydrocarbon linker beyond 4 atoms, as is the 




Lu-N3, does not lead to substantial increases in 
binding affinities. Interestingly, linker length does seem to play a more important role 
in the internalization of the NTR1-targeted agents. For 
177
Lu-N1, the β-Ala linker gives 














Lu-N3 in spite of having a lower binding affinity. It 





Lu-N3, did not induce receptor-mediated internalization as 





Why the longer linker length would affect the ability of the pharmacophore to activate 
the NTR1 is not clear. Relative to internalization, linker length had little effect on efflux 
patterns of the radioconjugates. One noteworthy observation was the small decrease in 
percentage efflux from 4 to 24 h time points. This suggests that externalized 
radioactivity (decay normalized) is being recycled back into the cell. It seems unlikely 
that this is through a receptor-mediated process, but may be attributable to pinocytosis 
of effluxed radioactivity over time.  







pharmacophore contains several modifications that significantly reduce enzymatic 
degradation of the pharmacophore in vitro and in vivo [44]. Utilizing 
177
Lu-N1, our best 
performing conjugate, the stability of this NTR1-targeted agent was evaluated in PBS, 
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conditioned medium and human serum. No discernible degradation was observed from 
these conditions over a 24 h period. This is expected based on the reported in vitro 
stability data of analogs with similar modifications [44,84]. Thus, as anticipated, the 
DOTA and the hydrocarbon linkers did not significantly alter in vitro stability of the 
pharmacophore at least over the monitored time frame. While no in vitro degradation 






]NT(6-13) peptide, Gruaz-Guyon and 
co-workers have demonstrated that this pharmacophore does exhibit significant in vivo 
metabolism in as little as 15 min post-injection [44]. This is an important consideration, 
as others have pointed out, when evaluating in vivo data [85]. Although the stability 






Lu-N3, we assume similar 
stabilities given the relative similarity of the radioconjugates. 
177
Lu-N1 was chosen for preliminary in vivo investigations due to its superior in 
vitro properties. At the 4 h time point, very little of the administered radioactivity 
remained in the blood pool. The majority of the radioactivity (85% of the ID) was 
cleared by the renal system which contributed to the substantial level of accumulation 
in the kidneys (17.0 ± 2.2 %ID/g). Significant kidney accumulation was also observed 







]NT(6-13) pharmacophore demonstrated 
substantially less renal accumulation (2.4 ± 0.2 %ID/g at 3 h p.i.) [44]. The distinct 
differences between the two analogs may be explained by the charge of each 
radioconjugate. On the N-terminal portion of 
177
Lu-N1, the peptide contains three 
positively charged amino acid residues (i.e. lysine and two arginines) yielding a total +2 
charge for the radioconjugate. Comparatively, the N-terminus of LB119 has the same 
three amino acids, but the charge of the lysine amino acid has been neutralized, by 
conjugation, to yield a total +1 charge for the agent. For radiolabeled peptides, the 
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effect of charge and charge distribution on kidney accumulation has been well 
established [106,110,117]. In general, radiolabeled peptides with increasing positive 
charges tend to exhibit higher levels of kidney accumulation. This has been attributed, 
at least in part, to non-specific uptake by the surface proteins megalin and cubilin [111]. 
The non-specific nature of 
177
Lu-N1 uptake in the kidney was confirmed by 
observation that blocking studies did not reduce accumulation. 
177
Lu-N1 demonstrated excellent tumor uptake and retention with            
3.1 ± 0.4 %ID/g at the 4 h time point. In comparison to LB119, 
177
Lu-N1 demonstrated 
a 2 fold higher HT-29 tumor retention at 4 h than LB119 (1.41 ± 0.05 %ID/g) at 3 h 
post-administration. Given the structural similarities of the pharmacophores, the 
significant (P < 0.0001) increase in tumor uptake and retention of 
177
Lu-N1 may be 
attributable to the charge of the radioconjugate as observed with the kidneys. 
Alternatively, this dissimilarity may be due to the purity of the prepared 
radioconjugates. 
177
Lu-N1 was obtained as a peak-purified product from HPLC 
whereas LB119 was prepared without HPLC purification. The lack of purification of 
LB119 likely resulted in a small amount of unlabeled conjugate being co-injected with 
the radioconjugate, which may negatively impact NTR1 uptake. To what extent these 
factors play into the higher retention of the 
177
Lu-N1 is not clear at this time. Small 
animal SPECT/CT imaging studies demonstrated significant tumor accumulation at 2 h 
post-administration and overall agrees well with the biodistribution data obtained at the 






We investigated the steric impact of the DOTA chelator and the length of 







]NT(6-13) pharmacophore. In conclusion, we found that the DOTA does 
negatively impact the binding affinity of the studied NTR1-targeted peptide. Optimal 
binding affinity could be restored by incorporation of a 4-atom hydrocarbon linker. 
Our best candidate (
177
Lu-N1) demonstrated substantial tumor accumulation, but the 
increase in renal retention relative to other literature analogs is likely due to the higher 
overall positive charge of the agent. 
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Chapter 3:  
Investigation of the Biological Impact of Charge 




The neurotensin receptor 1 (NTR1) has been shown to be a promising target, 
due to its increased level of expression relative to normal tissue, for pancreatic and 
colon cancers. This has prompted the development of a variety of NTR1-targeted 
radiopharmaceuticals, based on the neurotensin (NT) peptide, for diagnostic and 
radiotherapeutic applications. A major obstacle for the clinical translation of 
NTR1-targeted radiotherapeutics would likely be nephrotoxicity due to the high levels 
of kidney retention. It is well-known that for many peptide-based agents, renal uptake 
is influenced by the overall molecular charge. Herein, we investigated the effect of 













Lu−K6), with the Lys moved closer (K6) or further away (K2) from 
the pharmacophore, were synthesized. In vitro competitive binding, internalization 
and efflux, and confocal microscopy studies were conducted using the NTR1-positive 
HT-29, human colon cancer cell line. The 
177/nat
Lu−K6 demonstrated the highest 
binding affinity (21.8 ± 1.2 nM) and the highest level of internalization       
(4.06% ± 0.20% of the total added amount). In vivo biodistribution, autoradiography, 
and metabolic studies of 
177





Lu−K6 gave the highest levels of in vivo uptake in 
NTR1-positive tissues, whereas 
177
Lu−K2 yielded nearly 2-fold higher renal uptake 
relative to the other radioconjugates. In conclusion, the position of the Lys (positively 
charged amino acid) influences the receptor binding, internalization, in vivo 
NTR1-targeting efficacy, and kidney retention profile of the radioconjugates. In 
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addition, we have found that hydrophobicity likely play a role in the unique 
biodistribution profiles of these agents. 
3.2 Introduction 
The neurotensin receptor 1 (NTR1) is a G-protein coupled receptor that has 
been linked to proliferative action in a number of cancers, including colon and 
pancreatic cancer [49,125]. In addition, or as a consequence of this proliferative 
pathway, NTR1 has also been shown to be overexpressed on the cellular surface of 
these cancers. These findings have resulted in significant interest in developing 
NTR1-targeted radiopharmaceuticals for diagnostic and therapeutic purposes 
[41,43–45,92,96,103,133,143]. To date, NTR1-targeted agents have been largely 
based on neurotensin (NT), a thirteen amino acid peptide that has demonstrated 
nanomolar binding affinity to the receptor. Researchers have principally focused on 
targeting vectors based on the last six (NT(8-13)) or eight (NT(6-13)) amino acids of 
the NT sequence. Of the two targeting vectors, the NT(6-13) peptide demonstrates a 
marginally higher binding affinity to the NTR1 [144]. One major obstacle that 
hampered the development of NTR1-targeted radiopharmaceuticals early on was the 
rapid proteolytic degradation of the NT in the serum [32,145]. This situation is 
aggravated by the inability of in vitro serum studies to adequately predict in vivo 
stability which led to significant underperformance of the NTR1-targeted agents in 
preclinical and clinical studies [41,85]. The in vivo instability of these agents has led 
to the development of more stable, synthetic derivatives of the NT pharmacophore, 
which demonstrate significantly better in vivo performance [43,84,92,143]. 
The development of receptor-targeted, radiotherapeutic agents based on small 
peptide targeting vectors has been an active area of research over the last three decade 
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[15,16,19]. However, the translation of these radiotherapeutic peptides, including 
NTR1-targeted agents, into the clinic has been, in many cases, hampered by high 
renal uptake which can result in dose-limiting toxicities [106,146]. A variety of 
reports have investigated both the mechanism and structure-activity relationships 
corresponding to the renal uptake and retention of radiolabeled peptides [106,110,116]. 
From these studies, it has been recognized that the molecular charge is a significant 
factor in the renal uptake of radiolabeled peptides, including NTR1-targeted agents 
which typically contain two to three positively-charged amino acids (Arg and Lys) 
[110,115]. This high renal uptake has been a major hurdle for the potential 
development and translation of radiotherapeutic, NTR1-targeted agents.  
Our laboratory has recently begun exploring the development of 







targeting vector (Lys-Pro-(N-α-Me)Arg-Arg-Pro-Dmt-Tle-Leu) [45]. Although this 
pharmacophore exhibits excellent NTR1-positive tumor uptake, it has a total charge 
of +2 and exhibits significant renal uptake, reducing its potential for radiotherapeutic 
applications. While the molecular charge/renal uptake relationship for NTR1-agents 
has been established, we are interested in determining if charge distribution impacts 
the receptor avidity and renal uptake and retention of these agents. Herein, we 
investigate the biological impact of the translation of the Lys
6
 relative to the rest of 
the pharmacophore. Using a series of NTR1-targeted agents, Figure 3.1, we explore 
the structure-activity relationship of these agents using in vitro and in vivo models of 






Acetonitrile, formic acid, N,N-diisopropylethylamine (DIEA), N,N-dimethyl- 
formamide (DMF), dichloromethane (DCM), N,N'-dicyclohexylcarbodiimide (DCC) , 
methyl-t-butyl ether, N-methylpyrrolidone (NMP), bovine serum albumin (BSA), 
sodium dodecyl sulfate (SDS), LysoTracker
TM
 Blue DND-22, CellLight® early 
endosome-green fluorescent protein (GFP) and CellLight® late endosome-red 
fluorescent protein (RFP) were purchased from Fisher Scientific (Fair Lawn, 
NJ).  Fluorenylmethyloxycarbonnyl (Fmoc)-protected natural amino acids, 
Fmoc-(D)leu-OH, Fmoc-Leu-Wang resin (100-200 mesh), and (1-cyano-2-ethoxy-2- 
oxoethylidenaminooxy) dimethylamino-morpholino-carbenium hexafluorophosphate 
(COMU) were purchased from NovaBiochem (Hoherbrunn, Germany). 
Fmoc-N-Me-Arg(Pbf)-OH was produced by ChemPep, Inc. (Wellington, FL). 
Fmoc-2,6-dimethyl-L-tyrosine (Dmt) was from Ontario Chemicals, Inc (Guelph, ON, 
Canada). Fmoc-Tle-OH was purchased from CreoSalus (Louisville, KY). 
Lutetium-177 chloride (
177
LuCl3) was obtained from Perkin Elmer (Waltham, MA) 
with a specific activity of 32.3 Ci/mg. Naturally abundant lutetium chloride (
nat
LuCl3), 
triisopropylsilane and 3,6-dioxa-1,8-octanedithiol were from Sigma-Aldrich (St Louis, 
MO). McCoy’s 5A medium (1X; Iwakata & Grace Mod.) with L-glutamine was 
obtained from Mediatech, Inc. (Manassas, VA). TrypLE
TM
 Express was purchased 
from Invitrogen (Grand Island, NY). Penicillin-Streptomycin solution and 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were from HyClone 
Laboratories, Inc (Logan, UT). Heparin was purchased from Elkins-Sinn, Inc (Cherry 
Hill, NJ). Fetal Bovine Serum (FBS) was purchased from Gibco
TM
 by Life 
Technologies Corporation (Grand Island, NY). BD Cytofix™ Fixation buffer was 
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purchased from BD Biosciences (San Jose, CA). The O.C.T compound for tissue 
embedding was from Sakura Finetek USA, Inc. (Torrance, CA). 
3.3.2 Cell culture 
The human colon cancer cell line HT-29 was obtained from American Type 
Culture Collection (Manassas, VA) and cultured under vendor-recommended 
conditions. Cells were passaged twice weekly in McCoy’s 5A medium supplemented 
with 10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37 °C in a 
humidified incubator containing 5% CO2. 
3.3.3 Mouse model 
All animal experiments were conducted in accordance with the Principles of 
Animal Care outlined by the National Institutes of Health and approved by the 
Institutional Animal Care and Use Committee of the University of Nebraska Medical 
Center. Eight-week-old CF-1 mice were obtained from Charles River Laboratories 
(Wilmington, MA). Animals were housed five per cage in a light- and 
temperature-controlled environment. Food and water were given ad libitum. 
3.3.4 Solid-phase peptide synthesis (SPPS)  
Peptides were synthesized on an automated solid-phase Liberty microwave 
peptide synthesizer from CEM (Matthews, NC), employing traditional Fmoc chemistry. 
Briefly, the Fmoc-Leu-Wang resin (100 µmol of the resin-substituted peptide anchors) 
was deprotected by piperidine, resulting in the formation of a primary amine from 
which the C-terminus of the growing peptide was anchored. Fmoc-protected amino 
acids (300 µmol) were activated with COMU and sequentially conjugated to the resin. 
The resulting peptide was orthogonally deprotected and cleaved from the resin by 
shaking in a cocktail consisting of triisopropylsilane (0.125 ml), water (0.125 ml), 
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3,6-dioxa-1,8-octanedithiol (0.125 ml), and trifluoroacetic acid (4.625 ml) for 3 h. The 
cleaved peptide was subsequently precipitated and washed thrice using cold (0 °C) 
methyl-tert-butyl ether (40 ml×3). The crude peptides were dried under vacuum.  
3.3.5 Synthesis of Cyanine5-K6 as fluorescent dye 
Cyanine5-K6 was synthesized by conjugation of the Cyanine5 (Cy5) carboxylic 
acid to the NH2-K6-Wang resin. Briefly, a mixture of Cy5-COOH (6 µmol), 
NH2-K6-Wang-resin (6 µmol), COMU (30 µmol) and DIEA (30 µmol) was dissolved 
in DMF and shaken overnight at room temperature. After the reaction, the Cy5-K6 was 
cleaved from the Wang resin and purified by HPLC.  
3.3.6 HPLC purification and analysis methodology 
HPLC/MS analyses were performed on a Waters (Milford, MA) e2695 system 
equipped with a Waters 2489 absorption detector and a Waters Q-Tof Micro 
electrospray ionization mass spectrometer. Sample purification for in vitro studies was 
performed on a Phenomenex (Torrance, CA) Jupiter 10 µm Proteo 250 × 4.6 mm C12 
column with a flow rate of 1.5 mL/min. For bulk sample purification, a Phenomenex 
Jupiter 10 µm Proteo 250 × 10 mm C12 column was used with a flow rate of         
5.0 mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid (solvent A) 
and acetonitrile containing 0.1% formic acid (solvent B). For unlabeled and 
177/nat
Lu-conjugates of K2, K4 and K6, an initial gradient of 85% A: 15% B linearly 
decreased to 70% A: 30% B over a 15-minute time period. At the end of the run time for 
all HPLC experiments, the column was flushed with the gradient 5% A: 95% B and 
re-equilibrated to the starting gradient. 
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3.3.7 Labeling with natLuCl3 
Naturally abundant Lutetium (
nat
Lu) was substituted for 
177
Lu in the ES-MS and 
in vitro binding studies. The conjugate (0.10 mg, 0.06 μmol) was dissolved in 
ammonium acetate buffer (0.5 M, 200 μL, pH 5.5) and mixed with a solution of 
nat
LuCl3 (1.7mg, 6 μmol). The solution was heated for 45 min at 90 °C. After cooling to 
room temperature, 
nat
Lu-conjugates were then peak purified by RP-HPLC. All 
nat
Lu-conjugates were ≥ 95% pure before mass spectrometric characterization and    
in vitro binding studies were performed. 
3.3.8 Radiolabeling with 177LuCl3 
The conjugate (50 µg, 30 nmol) was dissolved in ammonium acetate buffer  
(0.5 M, 100 μL, pH 5.5). 
177
LuCl3 (37 MBq, 1 mCi, 0.18 nmol) was added to the vial 
containing the conjugate, and the solution was heated for 45 min at 90 °C. To separate 
radiolabeled peptides from unlabeled peptides on the HPLC, 4-5 mg of CoCl2 was 
added and incubated for 5 min at 90 °C to increase the hydrophobicities of the 
unlabeled conjugates [132]. After cooling to room temperature, evaluation and 
purification of the radiolabeled conjugates were performed on a Waters 1525 binary 
pump equipped with a Waters 2489 absorption detector and a Bioscan (Poway, CA) 
Flow Count radiometric detector system. The collected radioconjugate was 
concentrated with an Empore (Eagan, MN) C18 high performance extraction disk 
followed by elution with ethanol/sterile saline solution (6:4, 400 μL) to provide the 
radiolabeled conjugates in high purity. When required, a BSA-saline solution was 
added to the radioconjugate to give a solution containing 0.5% BSA. 
3.3.9 Distribution coefficient 
The distribution coefficient was determined (n = 6, 2 technical (tech) and      
3 biological (bio) repeats) for each 
177
Lu-labeled radioconjugate. In a 1.5 ml centrifuge 
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tube, 0.5 mL of 1-octanol was added to 0.5 mL of phosphate-buffered saline (pH 7.4) 
containing the radiolabeled peptide (500,000 cpm). The solution was vigorously stirred 
for 2 min at room temperature and subsequently centrifuged (8000 x g, 5 min) to yield 
two immiscible layers. Aliquots of 100 µL were taken from each layer and the 
radioactivity of each was quantified by an LTI (Elburn, IL) Multi-Wiper nuclear 
medicine gamma counter.  
3.3.10 In vitro competitive binding studies 
As described previously [45,132], the half maximal inhibitory concentration 
(IC50) for each conjugate was determined (n = 6, 2 tech and 3 bio repeats) for each 
177












as the competitive radioligand for comparing the relative effectiveness of the unlabeled 
and labeled conjugates. HT-29 cells (~1×10
6
) were suspended in 100 µL of McCoy’s 
5A medium (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA) and incubated at 37 °C 
for  45 min in the presence of 
177
Lu-N1 (100,000 cpm, 100 µL) and various 
concentrations of the unlabeled conjugates and 
nat
Lu-conjugates (100 µL). At the end of 
the incubation, the cells were centrifuged, aspirated and washed with media five times. 
The cell-associated radioactivity was measured using a gamma counter and the IC50 
values determined by nonlinear regression using the one-binding site model of 
GraphPad Prism 5 (La Jolla, CA). 
3.3.11 In vitro internalization and efflux studies 
The in vitro internalization and efflux studies were performed as stated 
previously [45,132]. HT-29 cells (~1×10
6
) were suspended in 100 µL of McCoy’s 5A 
medium (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA). Cells were incubated at 
37°C with each 
177
Lu-radioconjugate (100,000 cpm) for up to 2 h. At 15, 30, 60 and  
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120 min time points, cells were washed five times with media to remove the unbound 
peptide. Surface-bound radioactivity was removed by washing the cells twice with an 
acidic buffer (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8). The amount of 
radioactivity remaining in each cellular pellet was assigned as the internalized fraction. 
The cellular uptake of the radioconjugates was presented as a percentage of total 
activity added with groups representing internalized and surface-bound radioactivity.  
For efflux studies, HT-29 cells (~1×10
6
) were incubated in six-well plates 
overnight. On the day of the experiment, HT-29 cells were incubated for 2 h at 37°C in 
the presence of 100,000 cpm of each 
177
Lu-radioconjugate. Cells were washed      
five times with medium (1 ml) to remove the unbound peptide followed by the addition 
of fresh medium. At 0, 0.5, 1, 2, 4 and 24 h, the medium for each time point was 
harvested for quantitative analysis of ligand efflux. Surface-bound radioactivity was 
removed by washing the cells twice with an acidic buffer (50 mM glycine-HCl/0.1 M 
NaCl buffer, pH 2.8). The cells were then lysed using a 10 % aqueous SDS solution to 
quantify the remaining internalized fractions. The radioactivity in the effluxed, 
surface-bound and internalized fractions for each radioconjugate was determined using 
a gamma counter. The effluxed fraction is expressed as a percentage of the total 
radioactivity in the well, which is the sum of the effluxed, surface-bound and fraction 
remaining in the cell.  
3.3.12 Confocal microscopy images of the Cy5-K6 
HT-29 cells were cultured on a Lab-Tek chambered #1.0 borosilicate 
coverglass disk (4 well) overnight at a concentration of 0.05 million cells per well. The 
CellLight
TM
 early endosome-GFP and CellLight
TM
 late endosome-RFP reagents were 
added to each well and incubated overnight in a humidified atmosphere with 5% CO2 at 
37 ºC. After incubation, HT-29 cells were washed with fresh medium and incubated 
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with LysoTracker Blue DND-22 for 2 h at a concentration of 1 nM. After again 
washing the cells, the Cy5-K6 was diluted in McCoy’s 5A medium and incubated with 
HT-29 cells. At 0.5, 2 and 24 h, the unbound Cy5-K6 was washed off. The 
formaldehyde fixation buffer was added to the cells and incubated for 10 min. The cells 
were washed with PBS and fluorescent images were obtained using an excitation 
wavelength of 373 nm (blue), 488 nm (green), 555 nm (red) and 650 nm (Cy5). 
Confocal microscopy images were taken on a Leica LSM 510 META Microscope 
equipped with an argon laser. 
3.3.13 In vivo biodistribution studies 
Biodistribution studies were carried out using healthy CF-1 mice. Each mouse 
(average weight, 25 g) received an intravenous bolus, via the tail vein, of 
177
Lu-radiolabeled K2, K4 or K6 (370 kBq, 10 µCi) in 100 μL of saline. At 1, 4 and 24 
h post injection, the mice were sacrificed and the amounts of radioactivity in the tissues 
were counted with a NaI (Tl) well detector from AlphaSpectra, Inc. (Grand Junction, 
CO). The excised tissues were weighed and results were expressed as percentage of 
injected dose per gram of tissue (%ID/g). Blocking studies were carried out by 
co-injection with excess unlabeled K6 (250 μg).  
3.3.14 Metabolic studies in mice 






Lu-K6 (37 MBq, 
1mCi) was injected in the tail vein of CF-1 mice. After 10 min, blood was drawn from 
the heart of the animals under anesthesia and collected with prechilled polypropylene 
tubes, containing heparin, and placed on ice. Blood samples were centrifuged at    
2000 g/ 4°C for 10 mins, plasma was collected, mixed with chilled acetonitrile (1:1 v/v 
ratio), and centrifuged at 15,000 g/4°C for 10 min. Supernatants were concentrated to a 
smaller volume under a gentle N2 gas, diluted with saline, and filtered through a Millex 
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GV filter (0.22 μm). After 1 h, urine was collected, filtered with a Millex GV filter 
(0.22 μm). All samples were subsequently analyzed by RP-HPLC using the conditions 
previously stated.  
3.3.15 Autoradiography of the kidney 
The kidneys were collected from the metabolic studies, washed with deionized 
water, dried and immediately embedded in O.C.T compound on dry ice. Cryostat 
sections (10 µm) of tumor sample were exposed to the phosphor plate for 2 days. The 
phosphor plate was subsequently scanned by a Typhoon FLA 9500 variable mode 
imager (GE Lifesciences) at a 10 µm resolution.  
3.3.16 Statistical analysis 
Comparisons of groups for in vitro and in vivo studies were analyzed by the 
unpaired two-tailed Student’s t test. P values of less than 0.05 were considered 
statistically significant. 
3.4 Results 
3.4.1 Synthesis and radiolabeling  
Three NT analogs (Figure 3.1) with linking groups consisting of one lysine (Lys) 







NT(7-13), where X= Lys-(D)Leu-(D)Leu-(D)Leu-(D)Leu, K2; (D)Leu-(D)Leu-Lys-     
(D)Leu-(D)Leu, K4; and (D)Leu-(D)Leu-(D)Leu-(D)Leu-Lys, K6, were synthesized by 
SPPS. The three analogs, K2, K4 and K6, were named based on the position of Lys in 
the peptide sequence. RP-HPLC retention time, mass spectrometric identification and 
yields of the unlabeled conjugates and 
nat
Lu-conjugates are listed in Table 3.1. The 
isolated yields of the conjugates were relatively poor, likely due to the sterics resulting 
from conjugation to the secondary amines of the prolines and (N-α-Me)Arg [3]. The 
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purified conjugates were subsequently radiolabeled with 
177/nat
LuCl3 (t½ = 6.75 d) by 
co-incubation in an ammonium acetate buffer (pH = 5.5) for 45 min at 90 °C. The 






Lu-K6 were 77.5%, 79.14% and 
75.88%, respectively. In addition to the radioconjugates, a Cy5 fluorescent analog of 
K6 (Cy5-K6) was synthesized in order to perform cell trafficking studies. Cy5-K6 was 
prepared directly from SPPS, Figure 3.2, with an overall isolated yield of 2.5%. 
3.4.2 Distribution coefficient 
To evaluate the impact of the Lys position on the water solubility of the 
radioconjugates, octanol-PBS distribution coefficients at pH 7.4 were measured. The 






Lu-K6 were -2.53 ± 0.02,       
-2.59 ± 0.02 and -2.63 ± 0.01, (P < 0.05), respectively. While, as expected, the 






Lu-K2, indicating that movement of the Lys closer to pharmacophore 
increases hydrophilicity, albeit slightly. 
3.4.3 In vitro competitive binding studies 
The NTR1 binding affinity of the unlabeled conjugates and 
nat
Lu-labeled 
conjugates was investigated by competitive binding studies using HT-29 cells. The IC50 
values are given in Table 3.1. For the unlabeled conjugates, the IC50 value for K2 was 
the highest (P < 0.001) signifying the poorest binding analog investigated. In contrast, 
K6 had the lowest IC50 value (P < 0.001) indicating the highest affinity to the NTR1. 
For the 
nat






Lu-K2). This reveals that the proximity of the Lys to the 
pharmacophore plays a role in increasing the binding strength of the conjugate to the 


































Table 3.1. Characterization of K2, K4 and K6. 










Yields IC50 ± SD 
(nM) 
K2 962.2 962.5 8.9 5% 48.6 ± 1.2 
K4 962.2 962.5 8.8 3% 31.0 ± 1.1 
K6 962.2 962.0 8.0 4% 21.8 ± 1.2 
nat
Lu-K2 1048.2 1048.5 8.8 69% 35.6 ± 1.1 
nat
Lu-K4 1048.2 1048.6 7.4 76% 23.5 ± 1.1 
nat




3.4.4 In vitro internalization and efflux studies 
The effect of the position of the positive charged amino acid (Lys) on the rates 
of internalization (Figure 3.3) and efflux (Figure 3.4) of the radioconjugates was 
investigated in HT-29 cells. At time points 15, 30, 60 and 120 min, the cellular uptake 
(internalized and surface-bound radioactivity) of the radioconjugates was represented 
as a percentage of total activity added. 
177
Lu-K6 exhibited a statistically higher level of 




Lu-K4 at each time point from 15 min 




Lu-K4 was not significantly 
different over the initial 60 min time period. However, by 120 min post-incubation, a 
statistically significant increase was observed for 
177
Lu-K4. At the 120 min 
post-incubation time point, the overall uptake for the radioconjugates were 
177
Lu-K6 
(4.06 ± 0.20%) > 
177
Lu-K4 (2.64 ± 0.04%) > 
177
Lu-K2 (1.91 ± 0.09%).  
Efflux studies were conducted by incubating the radioconjugates with HT-29 
cells for 2 h, washing the cells with media to remove extracellular radioactivity and 
monitoring the release of radioactivity from the cells into the extracellular environment. 








Lu-K6 were calculated at the 0.5, 1, 
2, 4 and 24 h time points. By the 1 h time point, the effluxed fraction for 
177
Lu-K6 




Lu-K4 (24.78 ± 0.43% 
and 25.15 ± 0.93% respectively, P < 0.0001). Statistically lower levels of efflux were 
observed for 
177
Lu-K6 relative to the other radioconjugates for the remaining time 
points. By the 24 h time point, 
177
Lu-K6 had effluxed only 20% of the internalized 





















Lu-K6 (internalization and 













Lu-K6 by HT-29 




3.4.5 Confocal studies of the Cy5-K6 
Using HT-29 cells, confocal microscopy images of the Cy5-K6 (pink) were 
taken at 0.5, 2 and 24 h, Figure 3.5. Additionally, early endosome (Rab5a, green), late 
endosome/lysosome (Rab7a, red) and acidic compartments (LysoTracker™, blue) 
were stained and their colocalization with Cy5-K6 quantified, Table 3.2. At 30 min 
post-incubation, the Cy5-K6 was shown primarily at the surface of the HT-29 cells with 
a small fraction of the Cy5-K6 entering the cell and co-localizing with the early 
endosome marker (green). By 2 h post-incubation, Cy5-K6 had distributed into vesicles 
that contained all three markers with low to moderate correlation. The Cy5-K6 
demonstrated strong correlation/retention in vesicles that were both Rab7a- and 
LysoTracker™-positive by the 24 h post-incubation time point. 
3.4.6 In vivo biodistribution studies 












Lu-K6, were effectively cleared from the blood after 4 h 
post-injection (0.04 ± 0.02 %ID/g, 0.06 ± 0.08 %ID/g and 0.03 ± 0.03 %ID/g, 





substantially higher levels of liver uptake and retention, relative to 
177
Lu-K4. At 1 h, the 




Lu-K6 were 5.64 ± 0.47 %ID/g and          




Lu-K6 had dropped modestly to 4.73 ± 0.75 %ID/g and            












Figure 3.5. Confocal microscopy images of HT-29 cells with GFP-Rab5a, RFP-Rab7a, 












Table 3.2. Colocalization of Cy5-K6 
Overlap coefficient 30 min (n=4) 2 h (n=4) 24 h (n=6) 
Rab7a+ and LysoTracker+ 0.80 ± 0.12 0.75 ± 0.07 0.73 ± 0.09 
Rab7a+ and Cy5-K6+ 0 0.56 ± 0.18 0.75 ± 0.13 
LysoTracker+and Cy5-K6+ 0 0.49 ± 0.14 0.76 ± 0.15 









Lu-K6 demonstrated significantly higher lung uptake             
(5.08 ± 1.31 %ID/g) at 1 h post-injection relative to the other conjugates              
(< 1.11 ± 0.15 %ID/g). The substantial level of uptake in the liver and lung prompted us 
to investigate if the biodistribution of the radioconjugates was hindered by aggregate 
formation. BSA has been shown to inhibit the aggregation of peptides/proteins in 
solution [147,148]. The three radioconjugates were mixed with saline containing   
0.5% BSA, to impede any potential aggregation of the radioconjugates. With this in 
hand, the 1 h biodistribution experiments were repeated (data presented in the 
supporting information) and yielded no substantial changes in organ uptake and overall 
distribution profiles.  




Lu-K6 were statistically lower than that 
of 
177
Lu-K2 at all time points. At 1 h, the kidney uptake of 
177
Lu-K2 was         




Lu-K6        
(64.8 ± 10.81 %ID/g and 68.98 ± 6.22 %ID/g, respectively). By 24 h post-injection, the 
kidney retention of 
177
Lu-K2 had decreased substantially to 77.75 ± 10.15 %ID/g, but 




Lu-K6 (48.75 ± 9.59 %ID/g and     
43.96 ± 6.92 %ID/g, correspondingly).  
To evaluate the in vivo targeting capabilities of the NTR1-targeted agents, the 
uptake of the radioconjugates in the small and large intestines (NTR1-positive tissues) 




Lu-K6 demonstrated a 
statistically higher uptake (P < 0.001) in the small intestines (e.g., 4.25 ± 0.75 %ID/g 
and 4.46 ± 0.58 %ID/g, correspondingly) relative to 
177
Lu-K2 (2.72 ± 0.48 %ID/g). By 




Lu-K6 retained 67.1 and 57.0 % of the 1 h uptake, 
while 
177
Lu-K2 preserved 66.2 % of the initial uptake. Similar trends of uptake and 
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retention for the radioconjugates were observed in the large intestines data. A blocking 
study was performed to demonstrate the NTR1-mediated nature of the intestinal uptake. 
Using the 
177
Lu-K6 as our model radioconjugate, the blocking study at 1 h 
demonstrated a substantial reduction of 82.1% and 62.6 % in small and large intestinal 
uptake, respectively. Important to note, substantial reduction in uptake due to 
NTR1-blocking was not observed in the kidneys or liver, suggesting this uptake is not 
NTR1-mediated. However, interestingly, the lung uptake of 
177
Lu-K6 was shown to be 
substantially lower upon NTR1-blocking implying it was NTR1-mediated.  
3.4.7 Autoradiography of the kidney 
The distribution of radioconjugates/radiometabolites in the kidneys at 10 and  
60 min post-injection was investigated using autoradiography, depicted in Figure 3.9. 






Lu-K6 show that even in the 
early time points, the radioactivity is largely localized in the cortex of the kidney. While 
the position of the Lys group does impact the extent of kidney retention, based on the 
biodistribution studies, these autoradiographic images demonstrate that it does not 















CF-1 mice. The blocking study was performed with co-administration of 
250 µg of K6. The radioactivity uptake of tissues is expressed as a 
percentage of injected dose per gram of tissue (%ID/g). Values are   
















CF-1 mice. The radioactivity uptake of tissues is expressed as %ID/g. 
















CF-1 mice. The radioactivity uptake of tissues is expressed as %ID/g. 




Figure 3.9. Autoradiographic images of kidneys sections from CF-1 mice obtained at 









3.4.8 Metabolic studies in mice 
To evaluate the metabolism of the radioconjugates in vivo, metabolic analyses 
were performed on the blood and urine at 10 and 60 min, respectively, Figure 3.10. For 
the blood metabolism studies, the recovery efficiencies of the radioactive components 
from the samples were ~70 %. At 10 min post-injection, there were substantially higher 




Lu-K4 (AUC: 22.56 
and 14.99, respectively) compared to 
177
Lu-K6 (AUC: 2.61). However, the relative 
percent of intact radioconjugate was similar, ranging from 70.6 – 74.4 %. Three 




Lu-K6, while five 
were found for 
177
Lu-K4. The radiometabolites isolated from the blood had shorter 
retention time relative to the intact radioconjugate suggesting an increased 
hydrophilicity. Urine analysis at the 1 h time point demonstrated that 43.2 %, 49.8 % 







respectively. Three to four major radiometabolites were observed for each 
radioconjugate. Correlative identification based on retention times of the 
radiometabolites in the blood and urine was somewhat obfuscated due the different 
experimental conditions (e.g., sample matrices, analyte concentrations, etc.) leading to 
shifts in retention times. However, the major radiometabolite peaks for both the blood 
and urine samples had similar retention times and, for the most part, shift patterns 
suggesting that many of the radiometabolites were likely chemically identical. 
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Lu-K6. (A) Metabolites of 
177
Lu-K2 in the blood at 10 min (upper) and in the urine at 60min (lower); 
(B) Metabolites of 
177
Lu-K4 in the blood at 10 min (upper) and in the urine 
at 60 min (lower); (C) Metabolites of 
177
Lu-K6 in the blood at 10 min 
(upper) and in the urine at 60 min (lower). 
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3.5 Discussion 
To date, NTR1-targeted radiopharmaceuticals have been largely based on two 
targeting vector constructs: NT(6-13) and NT(8-13) [43–45,84,103,133,143]. While 
the NT(8-13) contains all of the necessary interactions to ensure low nanomolar 
binding affinity to the NTR1, the NT(6-13) fragment includes a terminal Lys
6
 which 
has been used by a variety of investigators as a convenient functionalization site for the 
incorporation of chelation systems (e.g., DTPA and DOTA) [31,44,84]. Recently, our 







analog, based on work from Gruaz-Guyon and co-workers [44], in which the Lys
6
 
remained unfunctionalized (charged) [45]. This analog exhibited significantly higher 
uptake in NTR1-positive tissues and kidneys compared to reported analogs that contain 
a functionalized (non-charged) Lys
6 
[44,84]. In order to better understand the role Lys
6
 
plays on tissue uptake, we investigated the impact of positional translation of the Lys, 







Lu-K6, Figure 3.1 
Evaluation of the receptor binding affinity of the NTR1-targeted analogs 
revealed that the position of the lysine has a modest impact on receptor binding. 
Binding affinities were found to decrease correlatively as the lysine is translated away 
from the main pharmacophore suggesting that Lys
6
 has a role in stabilizing the 
receptor-ligand complex. Based on what is known concerning NTR1-ligand 
interactions [62], we posit that the lysine is able to form weak charge-charge 
interactions with the electronegative rim of the binding pocket. 
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.Evaluation of the receptor binding affinity of the NTR1-targeted analogs 
revealed that the position of the lysine has a modest impact on receptor binding. 
Binding affinities were found to decrease correlatively as the lysine is translated away 
from the main pharmacophore suggesting that Lys
6
 has a role in stabilizing the 
receptor-ligand complex. Based on what is known concerning NTR1-ligand 
interactions [62], we posit that the lysine is able to form weak charge-charge 
interactions with the electronegative rim of the binding pocket. The internalization 
efficacies of the NTR1-targeted agents were also found to correlatively decrease as the 





, is more efficient at inducing the internalization of the receptor, possibly due 
to enhanced stabilization/residence time of the NTR1-ligand complex. Efflux studies 




Lu-K4 exhibited significantly higher levels of 
externalization relative to 
177
Lu-K6. However, it is unclear to us how the structure of 
the NTR1-targeted agents resulted in this observation. 
The cellular trafficking of fluorescently labeled NTR1-targeted agents has been 
previously reported by Vandenbulcke, Falciani and co-workers [149,150]. From our 
multicolor confocal microscopy studies, the initial uptake (i.e., 30 minute time point) of 
the Cy5-K6 demonstrated that internalized fluorescence was taken up, as expected, into 
the early endosomal compartments. Interestingly, the rate of Cy5-K6 uptake was much 
slower in HT-29 cells than what was observed by Vandenbulcke and co-workers using 
NTR1-transfected COS-7 cells [150]. This may be due to a number of factors including 
inherent differences in the two cell line phenotypes and levels of NTR1 expression. At 
2h post-incubation, the Cy5-K6 demonstrated moderate levels of signal overlap    
(0.36 ± 0.11 – 0.56 ± 0.18) with the three compartmental markers. However, by 24 h of 
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continuous exposure to Cy5-K6, strong levels of overlap, 0.75 ± 0.13 and 0.76 ± 0.15, 
was observed for the Rab7a-positive (red) and Lysotracker™-positive (blue) vesicles, 
correspondingly. Both Rab7a and Lysotracker™ are markers for late 
endosomes/lysosomes. Given the 24 h time point, it seems likely that most of the 
Cy5-K6 has matriculated to its terminal location in the lysosomes. 
Using biodistribution studies in CF-1 mice, the in vivo targeting efficacy of the 
NTR1-targeted agents were evaluated. For our NTR1-positive tissue, we utilized the 
small and large intestines, which are known to be endogenously expressed in the mouse 




Lu-K6 were statistically higher 
than 
177
Lu-K2 at all time points with P < 0.01. Similarly, uptake in the large intestines 
followed the same trend, but did not meet statistical significance. Blocking studies for 
177
Lu-K6 confirmed the NTR1-mediated nature of the uptake in the intestinal tissues. 







uptake in the intestines suggests other factors than just binding affinity play a role in 
determining the in vivo NTR1-targeting efficacy of these agents.  
The comparison of 
177
Lu-K6 with our previously published analog 
177
Lu-N1, 






]NT(6-13) pharmacophore, yielded 
interesting disparities [45]. The in vitro binding and internalization characteristics of 
177/nat
Lu-N1 were similar to 
177
Lu-K6. However, the uptake of 
177




Lu-K4, in the small and large intestines were roughly two-fold or more 
higher than observed for 
177
Lu-N1. This increased uptake is likely associated with the 
decreased hydrophilicity of this series of agents relative to 
177
Lu-N1 (log Doct/water = 
-3.15 ± 0.05) leading to enhanced circulation time. Though, it is important to note, this 
speculation is based on NTR1-positive intestinal uptake from two different strains of 
mice (CF-1 and SCID) which may differ in the level of NTR1-expression. 
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All of the NTR1-targeted agents demonstrated significantly (P < 0.0001) higher 
kidney uptake (3-6 fold) than observed with the previously reported analog, 
177
Lu-N1. 
This uptake in the kidneys is not NTR1-mediated as demonstrated by our blocking 
study. It is well-known that radiolabeled peptides are taken up by the kidney through 
active (e.g., megalin and cubulin) and passive (e.g., pinocytosis) means [107,110]. 
Additionally, the overall charge of the radioconjugate has been shown to influence the 
extent of renal uptake [110]. Since the overall charge (+2) of 
177
Lu-N1 and this series of 
NTR1-targeted agents are identical, we attribute this substantial increase in uptake to 






Lu-K6. Currently, it is 
unknown which renal uptake mechanism(s) were enhanced as a result of the increased 
hydrophobicities of the NTR1-targeted agents.  
As demonstrated by autoradiography studies, the retention of the radioactivity 
in the kidney occurred in the cortex, which is consistent with literature reports for 
neurotensin and other small receptor-targeted peptides [22]. 
177
Lu-K2 demonstrated 




Lu-K6. Based on the distribution coefficients, the differences in the hydrophobicity 
of the radioconjugates were negligible. Additionally, no substantial differences in the 
metabolism of 
177
Lu-K2 relative to the other radioconjugates were noted. Currently, it 
is unclear why the structure of 
177
Lu-K2 yields such a significant increase in kidney 
uptake. We hypothesize that this dissimilarity is due to unexpected higher renal uptake 
by one of the uptake mechanisms for 
177






Lu-K6, unexpected retention was observed in the liver 
and/or lung. For the DTPA and DOTA containing NTR1-targeted agents reported to 
date, significant uptake in these tissues has not been observed [44,45,84,85,103]. Since 
103 
these peptides are significantly more hydrophobic than previously reported analogs, 
initial thoughts were that aggregation of the peptides might be contributing to the 
uptake in these non-target tissues. Yet, co-formulation with BSA did not substantially 
alter the biodistribution profiles of the three radioconjugates. Interestingly, some 
reported 
99m
Tc-NTR1-targeted agents have been shown to have high liver and lung 
uptake [42,92]. Distribution coefficients were not reported for these analogs. However, 
based on their structures, we conjecture that hydrophobicity may be a contributing 
factor. 
3.6 Conclusion 
In summary, we investigated the impact of Lys charge distribution on the 
biological performance of a series of NTR1-targeted peptides. It was found that 
localization of the Lys closer to the pharmacophore lead to modest, but significant, 
increases in NTR1 affinity and rates of NTR1-mediated internalization. In vivo 




Lu-K6) with the Lys 
functionality closest to the targeting vector. The charge distribution of the Lys had an 
unexpected and substantial impact on uptake in the liver, lungs and kidneys. 
Additionally, the comparison of these findings with the literature suggests that the 
hydrophobicity plays a significant role in uptake in both NTR1-positive and 




Chapter 4:  
Design and Development of Competitive inhibitors to 




The application of radiolabeled NT analogs for detecting and treating 
NTR1-positive tumors has been comprised by rapid in vivo degradation. Some of the 
enzymes responsible for the degradation of NTR1-targeted analogs are known, 
including thimet oligopeptidase (TOP), neutral endopeptidase (NEP) and the 
angiotensin 1-converting enzyme (ACE). To investigate if inhibiting these enzymes 
can improve the efficacy of NT based analogs, we evaluated the co-administration of 
several known inhibitors and competitive substitutes of these enzymes. In vivo 
biodistribution studies using HT-29 tumor xenograft mice demonstrated that the 
co-administration with enzyme inhibitor, phosphoramidon (PA) significantly increased 
the in vivo tumor uptake from 5.55 ± 1.54 %ID/g (control) to 8.39 ± 0.63 %ID/g (with 
PA). The other agents tested, including the IPP (ACE inhibitor), bradykinin 
(competitive substrates for the peptidases that degraded NT) and peptide fragment of 
NT (Pro-Arg-Arg-Pro-Tyr), were not effective at inhibiting in vivo degradation and 
increasing NTR1-mediated uptake.  
4.2 Introduction  
The development of targeted diagnostic and radiotherapeutic agents for cancers 
has long been an objective for biomedical sciences [9,16,20,26,30,152,153]. 
Neurotensin (NT) receptors have been an active area of interest for targeted agent 
development due to the overexpression of these receptors on a variety of cancers 
[50,51,53,55,57–59,154]. There are currently three known neurotensin receptors 
(NTR1, NTR2 and NTR3) [64,67,155]. However, to date, NTR1 has received the most 
interest for radiopharmaceutical development due to: 1) the higher NTR1 expression on 
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prominent cancers, such as prostate and pancreatic tumors, and 2) the higher affinity of 
NTR1 for NT and NT-based analogs [67,156].   
NT was discovered over 40 years ago and has since been shown to have 
extensive neuromodulatory effects on both the central and peripheral nervous systems 
[67,75,79]. This neural hormone is a 13 amino acid peptide (Glu-Leu-Tyr-Glu-Asn- 
Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) which exhibits nanomolar affinity for the NTR1 
[75,76]. Because of this, NT was the logical starting point for the development of 
targeted agents for NTR1-positive cancers. Early work revealed that only the NT(8-13) 
fragment was necessary to achieve nanomolar binding affinity [82]. However, it was 
also found that the native NT(8-13) sequence was rapidly degraded in vivo, thus 
limiting the in vivo targeting efficacy of the agent [87,156]. Investigation into the 
enzymes responsible for this degradation implicated several peptidases, including 
thimet oligopeptidase (TOP) 3.4.24.15, neutral endopeptidase (NEP) 3.4.24.11 and the 
angiotensin-1-converting enzyme (ACE) 2.4.15.1 [87,88,127,157]. Specifically, TOP 













 amide bond. These finding 
have given the impetus for the development of stabilized NTR1-targeted analogs that 
employ single or multiple modification with alternative natural and/or non-natural 
amino acids to reduce in vivo degradation by these peptidases [31,32,43,44,93]. For 




,   
Tle
12
]NT(6-13) targeting vector [45,46]. These modifications have imparted 
substantially higher in vivo stability and targeting efficacy relative to the unmodified 
NT peptide, but are still relatively quickly degraded in vivo. Another recent approach, 
put forth by Nock, de Jong and co-workers, is the administration of enzymatic 
inhibitors to increase the in vivo stability of receptor-targeted peptides [97–100]. Using 
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analogs of targeted peptides that are in the clinic or under clinical development, these 
researchers have demonstrated that phosphoramidon (PA), a known inhibitor of NEP, 
could drastically increase the in vivo stability and targeting efficacy of the investigated 
agents.  
In this study, we explored the use of the enzymatic inhibitor approach in the 
context of NTR1-targeted peptides. Specifically, we examined whether the utilization 
of inhibitors can decrease the enzymatic degradation and increase the in vivo targeting 








]NT(6-13) radioconjugate. As part of 
this study, we investigated the enzymatic inhibitors PA (NEP inhibitor) and IPP, a 
tripeptide known to inhibit ACE. In addition, we investigated two peptide substrates: 1) 
bradykinkin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) a known substrate for both 
NEP and ACE [158–160]; and 2) a shortened peptide (SP) fragment (Pro-Arg- 
Arg-Pro-Tyr) of NT(6-13) that contains two of the three known cleavage sites. It was 
our hypothesis that these sacrificial substrates, which are co-administered at amounts 
magnitudes higher than the radioconjugate, would be able to temporarily saturate the 
enzyme(s) responsible for the degradation of the NTR1-targeted agents leading to an 



















4.3.1 Materials  
Acetonitrile, formic acid, N,N-diisopropylethylamine (DIEA), 
N,N-dimethylformamide (DMF), dichloromethane (DCM), N,N'-dicyclohexyl- 
carbodiimide (DCC) , methyl-t-butyl ether, N-methylpyrrolidone (NMP). Fluorenyl- 
methyloxycarbonnyl (Fmoc)-protected natural amino acids, Fmoc-β-Ala-OH, 
Fmoc-Leu-Wang resin (100-200 mesh), and (1-cyano-2-ethoxy-2-oxo- 
ethylidenaminooxy) dimethylamino-morpholino-carbenium hexafluorophosphate 
(COMU) were purchased from NovaBiochem (Hoherbrunn, Germany). 
Fmoc-N-Me-Arg(Pbf)-OH was obtained from ChemPep, Inc. (Wellington, FL). 
Fmoc-2,6-dimethyl-L-tyrosine (Dmt) was purchased from Ontario Chemicals, Inc 
(Guelph, ON, Canada). Fmoc-Tle-OH was procured from CreoSalus (Louisville, KY). 
Lutetium-177 trichloride (
177
LuCl3) was obtained from Perkin Elmer (Waltham, MA) 
with a specific activity of 32.3 Ci/mg. Naturally abundant lutetium trichloride 
(
nat
LuCl3), triisopropylsilane and 3,6-dioxa-1,8-octanedithiol were purchased from 
Sigma-Aldrich (St Louis, MO). McCoy’s 5A medium (1X; Iwakata & Grace Mod.) 
with L-glutamine was obtained from Mediatech, Inc. (Manassas, VA). TrypLE
TM
 
Express was procured from Invitrogen (Grand Island, NY). Penicillin-Streptomycin 
solution and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were 
obtained from HyClone Laboratories, Inc (Logan, UT). Fetal Bovine Serum (FBS) was 
purchased from Gibco
TM
 by Life Technologies Corporation (Grand Island, NY). 
Phosphoramidon sodium salt and bradykinin were procured from MP Biomedicals, 
LLC (Solon, OH). 
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4.3.2 Cell culture  
The human colon cancer cell line HT-29 was obtained from American Type 
Culture Collection (Manassas, VA) and cultured under vendor-recommended 
conditions. Cells were passaged twice weekly in McCoy’s 5A medium supplemented 
with 10% FBS, 100 IU/mL penicillin and 100 μg/mL streptomycin at 37 °C in a 
humidified incubator containing 5% CO2. 
4.3.3 Mouse model 
All animal experiments were conducted in accordance with the Principles of 
Animal Care outlined by the National Institutes of Health and approved by the 
Institutional Animal Care and Use Committee of the University of Nebraska Medical 
Center. Eight-week-old CF-1 mice and five-week-old Institute of Cancer Research 
severely combined immunodeficient (ICR SCID) mice were obtained from Charles 
River Laboratories (Wilmington, MA). Animals were housed five per cage in a light- 
and temperature-controlled environment. Food and water were given ad libitum. For 
xenograft model, bilateral HT-29 tumors were induced by subcutaneous injection of 
5.0×10
6
 cells in Matrigel (BD Biosciences). The tumors were allowed to grow for   
2-3 weeks reaching a maximal of 1 cm in diameter before the mice were utilized in 
pharmacokinetic studies. 
4.3.4 Solid-phase peptide synthesis (SPPS)  
As published previously, peptides were synthesized on an automated 
solid-phase Liberty microwave peptide synthesizer from CEM (Matthews, NC), 
employing traditional Fmoc chemistry. Briefly, the Fmoc-Leu-Wang resin (100 µmol 
of the resin-substituted peptide anchors) was deprotected by piperidine, resulting in the 
formation of a primary amine on the anchored amino acid. Fmoc-protected amino acids 
(300 µmol) were activated with COMU and sequentially conjugated to the resin. The 
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resulting peptide underwent cleaveage from the resin and orthogonal group 
deprotection by shaking in a cocktail consisting of triisopropylsilane (0.125 mL), water 
(0.125 mL), 3,6-dioxa-1,8-octanedithiol (0.125 mL), and trifluoroacetic acid (4.625 mL) 
for 3 h. The cleaved peptide was subsequently precipitated, filtered and washed thrice 
using cold (0 °C) methyl-tert-butyl ether (40 mL×3). The crude peptides were dried 
under vacuum.  
4.3.5 HPLC purification and analysis methodology 
HPLC/MS analyses were performed on a Waters (Milford, MA) e2695 system 
equipped with a Waters 2489 absorption detector and a Waters Q-Tof Micro 
electrospray ionization mass spectrometer. Sample purification for in vitro studies was 
performed on a Phenomenex (Torrance, CA) Jupiter 10 µm Proteo 250 × 4.6 mm C12 
column with a flow rate of 1.5 mL/min. For bulk sample purification, a Phenomenex 
Jupiter 10 µm Proteo 250 × 10 mm C12 column was used with a flow rate of         
5.0 mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid (solvent A) 
and acetonitrile containing 0.1% formic acid (solvent B). For unlabeled and 
177/nat
Lu-conjugates of N1, an initial gradient of 95% A: 5% B linearly decreased to 
85% A: 15% B over a 15-minute time period. For unlabeled SP, an initial gradient of 
95% A: 5% B linearly decreased to 90% A: 10% B over a 15-minute time period. For 
unlabeled IPP, an initial gradient of 98% A: 2% B linearly decreased to 92% A: 8% B 
over a 15-minute time period. At the end of the run time for all HPLC experiments, the 
column was flushed with the gradient 5% A: 95% B and re-equilibrated to the starting 
gradient. 
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4.3.6 Radiolabeling with 177LuCl3 
The conjugate (50 µg, 30 nmol) was dissolved in ammonium acetate buffer  
(0.5 M, 100 μL, pH 5.5). 
177
LuCl3 (37 MBq, 1 mCi, 0.18 nmol) was added to the vial 
containing the conjugate, and the solution was heated for 45 min at 90 °C. To separate 
radiolabeled peptides from unlabeled peptides on the HPLC, 4-5 mg of CoCl2 was 
added and incubated for 5 min at 90 °C to increase the hydrophobicity of the unlabeled 
conjugate. After cooling to room temperature, evaluation and purification of the 
radiolabeled conjugates were performed on a Waters 1525 binary pump equipped with 
a Waters 2489 absorption detector and a Bioscan Flow Count (Poway, CA) radiometric 
detector system. The collected radioconjugate was concentrated with an Empore 
(Eagan, MN) C18 high performance extraction disk followed by elution with 
ethanol/sterile saline solution (6:4, 400 μL) to provide the radiolabeled conjugates in 
high purity.  
4.3.7 In vitro competitive binding studies 
As described previously, the half maximal inhibitory concentration (IC50) for 
SP was determined (n = 6, 2 tech and 3 bio repeats) using the HT-29 human colon 











]NT(6-13)) served as the competitive radioligand for comparing the relative 
effectiveness of the unlabeled  conjugates. HT-29 cells (~1×10
6
) were suspended in 
100 µL of McCoy’s 5A medium (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA) and 
incubated at 37 °C for 45 min in the presence of 
177
Lu-N1 (100,000 cpm, 100 µL) and 
various concentrations (from 10
-4
 M to 10
-12
 M) of the SP (100 µL). At the end of the 
incubation, the cells were centrifuged, aspirated and washed with media five times. The 
cell-associated radioactivity was measured using a gamma counter and the IC50 values 
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determined by nonlinear regression using the one-binding site model of GraphPad 
Prism 5 (La Jolla, CA). 
4.3.8 In vivo biodistribution studies on mice 
Biodistribution studies were carried out both using healthy CF-1 mice and 
xenograft SCID mice. For biodistribution studies on CF-1 mice, each mouse (average 
weight, 30 g) received an intravenous bolus, via the tail vein, of 
177
Lu-radiolabeled N1 
(370 kBq, 10 µCi) in 100 μL of saline alone as a control, or with PA (300 µg), IPP   
(300 µg), SP (500 µg) or BK (500 µg). For biodistribution studies on xenograft mice, 
each mouse (average weight, 25 g) received an intravenous bolus, via the tail vein, of 
177
Lu-radiolabeled N1 (370 kBq, 10 µCi) in 100 μL of saline alone as a control, or with 
PA (300 µg), or BK (500 µg). At 1 h post injection, the mice were sacrificed and the 
amounts of radioactivity in the tissues were counted with a NaI (Tl) well detector from 
AlphaSpectra, Inc. (Grand Junction, CO). The excised tissues were weighed and results 
were expressed as percentage of injected dose per gram of tissue (%ID/g).  
4.3.9 Statistical analysis 
Comparisons of groups for in vitro and in vivo studies were analyzed by the 
unpaired two-tailed Student’s t test. P values of less than 0.05 were considered 
statistically significant.  
4.4 Results 
4.4.1 Synthesis of the peptides and radiolabeling of N1  
The structures of the N1, PA, IPP, BK and SP peptides are depicted in    
Figure 4.1. N1, IPP and SP were synthesized by SPPS and purified and characterized by 
LC-MS. PA and BK were purchased from commercial sources. Mass spectrometry, 
HPLC retention times and overall synthetic yields for the synthesized peptides are 
113 
given in Table 4.1. Yields for N1 were significantly lower than IPP or SP, which can be 
attributed to the relative length and increased steric restraints of the N1 peptide [45].  
Radiolabeling of N1 with 
177
LuCl3 was carried out in an ammonium acetate 
buffer (pH 5.5) at 90°C for 45 min. The radioconjugation reaction was examined by 
HPLC and found to give > 85% radiochemical yield. The radioconjugate was purified 
and characterized by HPLC. The retention time of the radioconjugate (9.8 min) was 
consistent with what was previously reported [45]. 
4.4.2 In vitro competitive binding studies 
To confirm NTR1 binding affinity of N1, competitive binding studies were 
performed for both N1 and 
177
Lu-N1 using HT-29 human colorectal cancer cells. The 
resulting IC50 value for both compounds were consistent with previous accounts [45]. 
Since the SP is a fragment of the NT(8-13) targeting vector, the IC50 of this fragment 
was evaluated to confirm negligible binding to the NTR1. SP demonstrated no binding 
over the concentrations investigated and was found to have an IC50 of > 0.1 mM. 
4.4.3 In vivo biodistribution studies using CF-1 mice 
The 1 h p.i. biodistribution profiles of 
177
Lu-N1 in a CF-1 mouse model alone and 
co-administered with PA, BK, SP or IPP are shown in Figure 4.2. 
177
Lu-N1 cleared 
from the blood rapidly with only 0.08 ± 0.01 %ID/g remaining at 1 h. The 
co-administration of IPP and SP had no effect on the blood retention of 
177
Lu-N1. 
However, co-injection with PA and BK did increase the blood retention of the 
radioconjugate to 0.17 ± 0.06 %ID/g and 0.29 ± 0.11 %ID/g, respectively. The tissues 
that demonstrated the highest degree of uptake of the NTR1-targeted agents is the small 
and large intestines and the kidney. Intestinal uptake has been shown to be due to the 






Figure 4.1. The structures of 
177










Table 4.1. Characteristics of N1, SP and IPP. 










1540.9 1541.9 13.9 11.1% 
SP Pro-Arg-Arg-Pro-Tyr 686.4 687.4 7.0 75.5% 




Thus, intestinal uptake, particularly the small intestines, can serve as a positive control 
from which to judge the in vivo targeting efficacy of the various formulations. 
177
Lu-N1 
demonstrated a small intestine uptake of 3.21 ± 0.20 %ID/g. Co-administration of the 
SP and IPP had either no effect or a slightly negative effect, in the case of IPP, on the 
NTR1-mediated uptake of 
177
Lu-N1. Conversely, co-formulation with PA and BK 
increased small intestine uptake to 4.20 ± 0.34 %ID/g and 5.06 ± 0.54 %ID/g, 
correspondingly. While similar, the trend in large intestinal uptake of 
177
Lu-N1 largely 
reflected that of the small-intestines, with exception to the BK co-formulation. The 
co-administration of BK yielded a substantial increase in uptake of the radioconjugate 
(4.90 ± 0.85 %ID/g).  
The observed kidney uptake (13.21 ± 0.36 %ID/g) of 
177
Lu-N1 alone reflects 
the fact that 
177
Lu-N1, as with most small peptides, are excreted primarily through the 
renal system. It has been demonstrated that this kidney uptake is not NTR1-mediated, 
but rather is based on non-specific mechanisms of uptake [45]. Co-injection of SP and 
IPP with 
177
Lu-N1 had no substantial impact on kidney uptake. However, the 
co-administration with PA and BK yielded significantly (P < 0.005) higher levels of 










Figure 4.2. Biodistribution studies on CF-1 mice at 4 h post-injection. (n=7 for 
177
Lu-N1, n=5 for the other group).  
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Lu-N1 formulations with the enzymatic inhibitors were next evaluated in 
an HT-29 human colon cancer xenograft mouse model (Figure 4.3). Taking the results 
from the CF-1 biodistribution studies into account, only 
177
Lu-N1 alone and 
formulations with PA and BK were investigated in the xenograft model. 
Biodistribution profiles of the SCID model were largely congruent with the data 
obtained from the CF-1 mouse model. 
177
Lu-N1 uptake in the NTR1-positive, small 
intestine was 5.26 ± 1.08 %ID/g. Co-administration of
 177
Lu-N1 with PA          
(7.04 ± 1.13 %ID/g, P < 0.05) and BK (8.04 ± 1.11 %ID/g, P < 0.01) demonstrated a 
corresponding 1.3-fold and 1.5-fold higher radioactivity accumulation compared to 
177
Lu-N1 alone. In the large intestine, the 
177
Lu-N1 co-injection with BK exhibited the 
highest uptake (9.34 ± 1.13 %ID/g, P < 0.0001). In contrast, no significant increase in 
large intestine uptake was observed for the 
177
Lu-N1 co-injection with PA         
(2.22 ± 0.29 %ID/g), as compared to 
177
Lu-N1 alone (2.03 ± 0.55 %ID/g).  
Uptake of the 
177
Lu-N1 in the NTR1-positive, HT-29 tumors was           
5.55 ± 1.54 %ID/g. The tumor uptake increased approximately 1.5-fold for the 
co-administered formulation with PA (8.39 ± 0.63 %ID/g). However, the tumor uptake 
of 
177
Lu-N1 co-injected with BK (3.95 ± 0.57 %ID/g) was not significantly different 
with the 
177
Lu-N1 alone. Interestingly, compared to the CF-1 data, the kidney uptake of 
the three groups was not significantly different with uptake values ranging from    









Figure 4.3. Biodistribution studies on colon cancer xenograft SCID mice at 1 h 




During the development of NTR1-targeted peptides, it was quickly realized that 
analogs based on the native NT targeting vector were rapidly degraded. This prompted 
the development of NT targeting vectors that are resistant to proteolytic degradation to 
increase in vivo stability and maintain targeting viability. While this approach has 
resulted in more stable and effective imaging and therapeutic agents, degradation of the 
structurally modified peptides still occurs and is a determinant to optimal 







]NT(6-13) targeting vector and have demonstrated that this 
agent is still quickly degraded (e.g., 30% in 10 min) in the blood [46]. The goal of this 
study was to investigate if inhibition of the enzymes responsible for the degradation of 
NTR1-targeted agents resulted in a significant increase in in vivo targeting. This 
premise is based on prior work that demonstrated that receptor-targeted peptides 
susceptible to metabolism by NEP demonstrated significantly higher in vivo targeting 
when PA, a known NEP inhibitor, was co-administered [97,98,101,161].  
The metabolism of NT based analogs has been attributed to several 
metallopeptidases, including TOP, neurolysin, NEP and ACE. TOP is a 









 of NT is attributed to the 
metalloendopeptidases neurolysin and NEP [127,157]. Lastly, ACE has been shown to 




 positions. For the aims of this study, we utilized several 
inhibitors of these peptides to evaluate the biological impact on the in vivo efficacy of 
NTR1-targeted agents. PA is a potent and relatively selective inhibitor of NEP     
(IC50 = 34 nM), but has also shown inhibitor activity for other metalloproteases 
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including ACE (IC50 = 78 µM) [163]. IPP is a tripeptide that had demonstrated 
inhibitory effects (IC50 = 5 µM) against ACE [164]. BK is a potent vasodilator and a 
substrate of ACE and NEP [165,166]. It is envisioned that BK would act as a 
“sacrificial” inhibitor, temporarily saturating ACE and NEP, thus temporally reducing 
the rate of degradation of NTR1-targeted peptides. Lastly, in the same vein, SP, a 
fragment of the NT(8-13) targeting vector, contains two of the three known cleavage 
sites. However, due to these proteases being endopeptidases, it is expected that SP 
would be a good inhibitor of TOP, but not necessarily neurolysin or NEP. 
Our initial investigation into the ability of enzymatic inhibitors to increase the 
in vivo targeting efficacy of NTR1-targeted agent was carried out using a CF-1 mouse 
model. Utilization of SP and IPP demonstrated no discernable effects with regard to the 
biodistribution profile of 
177
Lu-N1. Uptake of the radioconjugate into the 
NTR1-positive, small and large intestines remained unchanged. This establishes that 
the inhibitors, given at relatively high doses, were ineffective at increasing the in vivo 
efficacy of the NTR1-targete agent utilized in this study. The reason for this failure may 
be due to 
177
Lu-N1, which uses a modified (i.e., stabilized) targeting vector, no longer 
being a good substrate for ACE and TOP. If so, this implies that ACE and TOP are not 
the primary enzyme(s) responsible for the in vivo degradation of stabilized, 
NTR1-targeted agents. Conversely to this finding, the utilization of PA and BK had a 
marked impact on the uptake in the small intestines. Co-administration of 
177
Lu-N1 
with PA led to a 30.8% increase in radiotracer uptake, while co-formulation with BK 
led to a 57.6% increase. BK also had a substantial impact on the uptake in the large 
intestines with an increase of 301.6%. Given the selectivity of PA for NEP, it seems 
reasonable to conclude that NEP, through proteolytic cleavage, does effect the in vivo 
efficacy of stabilized NTR1-targeted agents. This is consistent with what has been 
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observed for other neuropeptide-based analogs [97,98,101,102]. Utilization of BK 
resulted in the largest increase in NTR1-mediated uptake. However, the interpretation 
of the BK impact was obscured, due to its known vasodilation effects. Whether the 
increased NTR1-mediated uptake of 
177
Lu-N1 was due to inhibition of ACE and NEP 
and/or its potent vasodilation effect increasing tissue perfusion was unclear.   
Taking the results from the CF-1 biodistribution studies into account, we 
decided to investigate 
177
Lu-N1 alone and the co-formulations including PA and BK in 
the HT-29 human colon cancer xenograft mouse model. The co-administration of PA 
and BK largely gave similar 
177
Lu-N1 uptake profiles compared to the CF-1 studies. 
One notable difference was the renal uptake. Co-administration of PA or BK did 
increased 
177
Lu-N1 kidney retention in CF-1 mice, but, interestingly, did not lead to a 
significant impact on renal uptake in SCID mice. The reason for the divergence in the 
renal uptake is unknown, but is possibly due to differences in the mouse strains. For the 
formulations investigated, the small and large intestines uptake profiles of the 
radiotracer were essentially identical for both mouse models. Using PA, HT-29 tumor 
uptake of 
177
Lu-N1 increased by 51.2% confirming that PA plays a positive role in 
increasing NTR1-mediated uptake through inhibition of NEP. However, the use of BK 
demonstrated no increase in HT-29 tumor uptake. BK is able to produce its vasodilation 
effect in normal vasculature by indirectly causing the vascular smooth muscle to relax 
[167,168]. In contrast, the vasculature of most solid tumors are known to generally lack 
smooth muscle [169]. Based on this, our finding strongly suggests that the positive 
effect of NTR1-mediated uptake in the intestines is a result of the vasodilation effect of 






Utilizing inhibitors and competitive substrates for proteases known to degrade 
NTR1-targeted agents, we investigated the impact of these agents on the in vivo 









]NT(6-13). At the doses utilized, IPP (ACE inhibitor) and 
SP (NT fragment) did not demonstrate a significant effect on NTR1-mediated uptake 
or the biodistribution profile of the radioconjugate. Co-injection of the radioconjugate 
with BK (ACE and NEP substrate) did demonstrate an increase in uptake in 
NTR1-positive tissues, but this increase was determined to be largely due to the 
increased perfusion due to the vasodilation effect of BK. However, in vivo studies in 
CF-1 and HT-29 tumor xenograft mice did demonstrate a substantial increase 
NTR1-mediated uptake in NTR1-positive non-target tissues and tumors. Overall, 
these studies demonstrate that PA (NEP and ACE inhibitor) is effective at 
enzymatically stabilizing and improving the in vivo efficacy of NTR1-targeted agents.   
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Chapter 5:    
Conclusions and Future Directions 
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NTR1 is overexpressed in several cancers due to its role as a growth pathway 
for cancer cells proliferation, invasion and migration [54,56,57,69,138,170,171]. The 
native ligand, NT, has been utilized as a base platform for the development of 
NTR1-targeted agents for the detection and treatment of receptor positive cancers 
[31,43,60,84,92,96]. However, the application of NT-based radiopharmaceuticals has 
been comprised by the decreased binding affinity due to the steric hindrance of various 
chelators [44,103]. In addition, the unstable nature of NT-based radiopharmaceuticals 
has led to a diminished amount of intact peptides that can accumulate at the target sites 
(e.g., tumors) [42–44,92,95]. Lastly, NT-based radiopharmaceuticals, as with most 
radiopeptides of small size, are primarily excreted via the renal system. As a 
consequence, the high kidney uptake of NTR1-targeted agents occurs which is a 
concern when considering its application for targeted radiotherapy [15,22]. To shed 
further light onto these problems as well as explore approaches that may improve the 
clinical potential of NT-based radiopharmaceuticals, we investigated the 
structure-activity relationships of various NTR1-targeted agents. Specifically, we 
explored possible strategies to restore binding affinity, determine the effect of charge 
distribution on the biological profile of NTR1-targeted agents and evaluate if peptidase 
inhibitors were able to increase the in vivo stability of a NTR1-targeted analog.  
As demonstrated in the bombesin analogs, the negative effect of macrocyclic 
chelator on the binding affinity of receptor-targeted agents could be diminished by the 
insertion of spacer groups between the macrocyclic chelator and the binding   
sequence [37,172]. To evaluate the effect of inserted spacers on the binding affinity of 







]NT(6-13)) with various spacers of different length (e.g., 
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null, β-Ala, 5-Ava and 8-Aoc) in Chapter 2. In vitro competitive binding, 
internalization and efflux studies were performed on all four NT analogs using HT-29 
human colon cancer cells. The in vitro competitive binding assays demonstrated that 
the binding affinity was significantly increased compared with the analog without a 
spacer. Specifically, the analog with a β-Ala spacer (
177
Lu-N1) could restore a binding 
affinity similar to that of the intact NT. In addition, the 
177
Lu-N1 internalized more 
rapidly and effluxed more slowly than the other analogs tested, indicating the high 
retention of this agent in the HT-29 cells. 
177
Lu-N1 also exhibited in vitro stability for 
24 h in PBS, conditioned medium and human serum. In vivo biodistribution and 
SPECT/CT imaging studies of 
177
Lu-N1 demonstrated excellent tumor accumulation        
(3.1 ± 0.4 %ID/g) in a NTR1-positive colon cancer xenograft model. We concluded 
that a spacer of β-Ala or longer could restore the binding affinity of NTR1-targeted 
agents containing DOTA. In the future, other spacers with different properties      
(e.g., hydrophobicity and charge) could be investigated to determine the effect these 
changes have on biological performance. 
 From the in vivo biodistribution study of 
177
Lu-N1, we observed the high 
kidney uptake, which could comprise the clinical therapeutic application of this agent. 
The high, non-specific kidney uptake is a common hurdle for the development of 
peptide-based radiopharmaceuticals. Based on numerous investigations concerning the 
mechanism and cause of peptide uptake in the kidneys, the charge of the NT-based 
radiopharmaceuticals has been shown to play an important role in the renal uptake. 
However, the effect of charge distribution of the NT-based radiopharmaceuticals on the 
biological profile, including the binding affinity and retention in non-target tissues  
(e.g., kidneys), has not been investigated. To investigate the influence of charge 
distribution on NTR1-targeted agents, we synthesized three analogs with the spacers 
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composed of Lys and D-Leu in Chapter 3. These analogs had the same net charge, but 
with different charge distributions through the sequence (K2, K4 and K6). The effect of 
the charge distribution was evaluated on the NTR1 binding, receptor-mediated uptake 
and in vivo biodistribution. With the movement of Lys towards the binding sequence, 
the binding affinity increased. The in vivo biodistribution of the non-target organs and 
receptor-positive organs showed different uptake patterns, indicating the influence of 
the charge distribution of the peptide. The noticeable uptake in the lung and liver of 
177
Lu-K2, K4 and K6 was most likely due to the hydrophobicity of these agents. The in 
vivo radiometabolites generated by the 
177
Lu-K2, K4 and K6 were also investigated. 
These studies demonstrated that even these “stabilized” NTR1-targeted agents undergo 
degradation in vivo. However, further studies to determine the chemical identity of the 
radiometabolites generated, including the molecular weight and sequence, have yet to 
be performed. With such information, the design of improved NT-based 
radiopharmaceuticals with higher in vivo stability will be possible.  
In the last study, we investigated the effect of selective inhibitors and 
competitive substrates for the enzymes responsible for the degradation of the NT-based 
radiopharmaceutical in Chapter 4. Using 
177
Lu-N1, the co-administration of PA (a NEP 
inhibitor) was found to increase NTR1-positive, tumor uptake 1.6 fold in colon cancer 
xenograft mice. However, with the co-administration of the other inhibitor, IPP (an 
ACE inhibitor), and competitive substrates (SP and BK), no increase in the 
receptor-mediated uptake was observed. The promising result from the 
co-administration of PA will encourage future studies to optimize the use of PA as well 
as the investigation of other inhibitors to improve the in vivo stability and potential of 
NTR1-targeted agents. 
128 
With the studies performed herein, we evaluated the structure-activity 
relationships of NTR1-targeted agents as well as explored approaches that could 
ultimately increase translational potential. It is expected that the strategies and insights 
found in this work will inspire the design of the next generation of NTR1-targeted 
agents. Ultimately, it is hoped that, with these new and improved analogs, the 
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